Development of novel therapeutic and diagnostic approaches utilizing tools from the physical sciences by Malalasekera, Aruni Peiris
  
DEVELOPMENT OF NOVEL THERAPEUTIC AND DIAGNOSTIC APPROACHES 
UTILIZING TOOLS FROM THE PHYSICAL SCIENCES 
 
by 
 
 
ARUNI PEIRIS MALALASEKERA 
 
 
 
 
B.Sc. (Hons), University of Colombo, Sri Lanka 2009 
 
 
 
 
AN ABSTRACT OF A DISSERTATION 
 
 
Submitted in partial fulfillment of the requirements for the degree 
 
 
 
DOCTOR OF PHILOSOPHY 
 
 
 
Department of Chemistry 
College of Arts and Sciences 
 
 
 
KANSAS STATE UNIVERSITY 
Manhattan, Kansas 
 
 
2016 
 
  
  
Abstract 
Numerous Proteases are implicated in cancer initiation, survival, and progression. Therefore, it is 
important to diagnose the levels of protease expression by tumors and surrounding tissues, which 
are reflected in blood and tissue samples. Nanoplatforms for Cathepsin(CTS) B and L, matrix 
metalloproteinases(MMP) 1, 2, 3, 7, 9, 13 and urokinase plasminogen activator(uPA) detection 
have been synthesized. Nanoplatforms feature a central dopamine-coated core/shell Fe/Fe3O4 
nanoparticle. Cyanine 5.5 is permanently tethered to the dopamine ligands via amide bonds. 
Tetrakis(4-carboxy-phenyl)porphyrin (TCPP) is co-tethered to Fe/Fe3O4/dopamine by means of 
protease consensus sequences. In the presence of a relevant protease sequence, it is cleaved, 
releasing TCPP from the nanoplatform. In contrast, Cy 5.5 will remain permanently tethered to 
the nanoparticle. Therefore, an extensive increase of emission intensity of the fluorescence signal 
from TCPP is observed. This permits the detection of the activity of proteases at femtomolar 
levels in biospecimens by fluorescence spectroscopy. 46 breast cancer and 20 healthy human 
blood serum samples were analyzed. Based on the expression pattern of analyzed enzymes, 
human breast cancer can be detected at stage I. By monitoring CTS B and L stage 0 detection 
may be achieved. This study demonstrates the feasibility of minimally invasive successful early 
cancer diagnosis. 
Immunosuppression is one of the hallmarks of aggressive cancers. Arginase is overexpressed in 
cancer patients, resulting in systemic immunosuppression. Two nanoplatforms for arginase 
detection have been synthesized. Both feature a central dopamine-coated core/shell Fe/Fe3O4 
nanoparticle to which cyanine 7.0 or cyanine 7.5 is tethered via amide bonds. In both 
nanoplatforms, cyanine 5.5 is linked to the N-terminal of the peptide sequence GRRRRRRRG. 
Arginine (R) reacts to ornithine (O) in the presence of arginase. According to our results 
  
obtained from fluorescence spectroscopy, the oligopeptides GRRRRRRRG and GOOOOOOOG 
differ in their chain dynamics. In the presence of arginase, and dependent on arginase activity, 
fluorescence increase of both nanoplatforms is observed, which is an indication that proton-
transfer quenching decreases when arginine gets converted to ornithine.  The novel assays permit 
the detection of active arginase within an hour. Additionally, Förster Resonance Energy Transfer 
(FRET) is observed in nanoplatforms featuring cy 5.5/7.0 pairs, resulting in picomolar detection 
limits. This is the first example of a “post-translational” enzyme sensor, in which the tether is 
subjected to chemical transformations of the aminoacid side chains and not cleaved by an 
enzyme, resulting in the modified mobility of the tether. The nanoplatforms do not show a 
fluorescence increase when incubated with NO-reductase, an enzyme indicative of 
immunoactivation, which also uses arginase as substrate. 
Copper dependent inhibitory activity of 10000 compound library has been studied against of 
Staphylococcus aureus. 53 copper- dependent hit molecules were recognized featuring extended 
thiourea core structure with NNSN motif. NMR titrations, UV/Vis studies have been performed 
for characterization of metal complexation and structure modeling. Chemoinformatic meta-
analysis of the ChEMBL chemical database confirmed the NNSNs as an unrecognized 
staphylococcal inhibitor, in spite of other compound groups in chemical screening libraries. This 
will lead to the development of novel class of antibacterial agents against Staphylococcus aureus. 
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Abstract 
Numerous Proteases are implicated in cancer initiation, survival, and progression. Therefore, it is 
important to diagnose the levels of protease expression by tumors and surrounding tissues, which 
are reflected in blood and tissue samples. Nanoplatforms for Cathepsin(CTS) B and L, matrix 
metalloproteinases(MMP) 1, 2, 3, 7, 9, 13 and urokinase plasminogen activator(uPA) detection 
have been synthesized. Nanoplatforms feature a central dopamine-coated core/shell Fe/Fe3O4 
nanoparticle. Cyanine 5.5 is permanently tethered to the dopamine ligands via amide bonds. 
Tetrakis(4-carboxy-phenyl)porphyrin (TCPP) is co-tethered to Fe/Fe3O4/dopamine by means of 
protease consensus sequences. In the presence of a relevant protease sequence, it is cleaved, 
releasing TCPP from the nanoplatform. In contrast, Cy 5.5 will remain permanently tethered to 
the nanoparticle. Therefore, an extensive increase of emission intensity of the fluorescence signal 
from TCPP is observed. This permits the detection of the activity of proteases at femtomolar 
levels in biospecimens by fluorescence spectroscopy. 46 breast cancer and 20 healthy human 
blood serum samples were analyzed. Based on the expression pattern of analyzed enzymes, 
human breast cancer can be detected at stage I. By monitoring CTS B and L stage 0 detection 
may be achieved. This study demonstrates the feasibility of minimally invasive successful early 
cancer diagnosis. 
Immunosuppression is one of the hallmarks of aggressive cancers. Arginase is overexpressed in 
cancer patients, resulting in systemic immunosuppression. Two nanoplatforms for arginase 
detection have been synthesized. Both feature a central dopamine-coated core/shell Fe/Fe3O4 
nanoparticle to which cyanine 7.0 or cyanine 7.5 is tethered via amide bonds. In both 
nanoplatforms, cyanine 5.5 is linked to the N-terminal of the peptide sequence GRRRRRRRG. 
Arginine (R) reacts to ornithine (O) in the presence of arginase. According to our results 
  
obtained from fluorescence spectroscopy, the oligopeptides GRRRRRRRG and GOOOOOOOG 
differ in their chain dynamics. In the presence of arginase, and dependent on arginase activity, 
fluorescence increase of both nanoplatforms is observed, which is an indication that proton-
transfer quenching decreases when arginine gets converted to ornithine.  The novel assays permit 
the detection of active arginase within an hour. Additionally, Förster Resonance Energy Transfer 
(FRET) is observed in nanoplatforms featuring cy 5.5/7.0 pairs, resulting in picomolar detection 
limits. This is the first example of a “post-translational” enzyme sensor, in which the tether is 
subjected to chemical transformations of the aminoacid side chains and not cleaved by an 
enzyme, resulting in the modified mobility of the tether. The nanoplatforms do not show a 
fluorescence increase when incubated with NO-reductase, an enzyme indicative of 
immunoactivation, which also uses arginase as substrate. 
Copper dependent inhibitory activity of 10000 compound library has been studied against of 
Staphylococcus aureus. 53 copper- dependent hit molecules were recognized featuring extended 
thiourea core structure with NNSN motif. NMR titrations, UV/Vis studies have been performed 
for characterization of metal complexation and structure modeling. Chemoinformatic meta-
analysis of the ChEMBL chemical database confirmed the NNSNs as an unrecognized 
staphylococcal inhibitor, in spite of other compound groups in chemical screening libraries. This 
will lead to the development of novel class of antibacterial agents against Staphylococcus aureus. 
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Chapter 1 - Introduction 
My research during my thesis from April 2012 to December 2015 in the Chemistry Department 
at Kansas State University under the guidance of Dr. Stefan Bossmann was concerned with 
applying various methods from the field of Physical Sciences to a variety of mechanistic and 
medicinal problems. My research has resulted in co-authorship of six publications in refereed 
journals, as well as co-inventorship of one patent. A seventh publication is in the process of 
being submitted.  
 
Publications: 
1. Wang, H.; Udukala, D. N.; Samarakoon, T. N.; Basel, M. T.; Kalita, M.; Abayaweera, G.; 
Manawadu, H.; Malalasekera, A.; Robinson, C.; Villanueva, D.; Maynez, P.; Bossmann, L.; 
Riedy, E.; Barriga, J.; Wang, N.; Li, P.; Higgins, D. A.; Zhu, G.; Troyer, D. L.; Bossmann, S. H., 
Nanoplatforms for highly sensitive fluorescence detection of cancer-related proteases. 
Photochem. Photobiol. Sci. 2014, 13 (2), 231-240. 
2. Fernando, A.; Malalasekera, A. P.; Yu, J.; Shrestha, T. B.; McLaurin, E. J.; Bossmann, 
S. H.; Aikens, C. M., Refined Insights in the Photochromic spiro-Dihydroindolizine/Betaine 
System. J. Phys. Chem. A 2015,119 (37), 9621-9629. 
3. Fernando, A.; Shrestha, T. B.; Liu, Y.; Malalasekera, A. P.; Yu, J.; McLaurin, E. J.; 
Turro, C.; Bossmann, S. H.; Aikens, C. M., Insights from Theory and Experiment on the 
Photochromic spiro-Dihydropyrrolo-Pyridazine/Betaine System. J. Phys. Chem. A 2016,120 (6), 
875-883. 
5. Dalecki, A. G.; Malalasekera, A. P.; Schaaf, K.; Kutsch, O.; Bossmann, S. H.; 
Wolschendorf, F. Combinatorial phenotypic screen uncovers unrecognized family of extended 
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thiourea inhibitors with copper-dependent anti-staphylococcal activity. Metallomics. 2016. 
6. Udukala, D. N.; Wang, H.; Wendel, S. O.; Malalasekera, A. P.; Samarakoon, T. N.; 
Yapa, A. S.; Abayaweera, G.; Basel, M. T.; Maynez, P.; Ortega, R.; Toledo, Y.; Bossmann, L.; 
Robinson, C.; Janik, K. E.; Koper, O. B.; Li, P.; Motamedi, M.; Higgins, D. A.; Gadbury, G.; 
Zhu, G.; Troyer, D. L.; Bossmann, S. H., Early Breast Cancer Screening Using Iron/Iron Oxide-
Based Nanoplatforms with Sub-Femtomolar Limits of Detection. Beilstein J. Nanotechnol 2016, 
accepted. 
7. Malalasekera, A. P.; Wang, H.; Samarakoon, T. N.; Udukala, D. N.; Ortega, R.; 
Shrestha, T. B.; Troyer, D. L.; Bossmann, S. H., Nanoplatforms for the Detection of Arginase 
Activities. Nanomedicine NBM 2016, in preparation. 
 
Patent: 
Malalasekera, A.P.; Wang, H.; Wendel, S. O.; Zhu, G.; Troyer, D. L.; Bossmann S. H. 
Nanoplatforms for Arginase, Indoleamine 2,3-Dioxygenase and Tryptophan 2,3-Dioxygenase 
Detection by Posttranslational Modification. 2015(WO201521821669):20pp. 
 
My thesis document is focused on my medicinal research, which I consider more valuable to 
society than my mechanistic research on photochromic compounds. I have been working on the 
evolution of the nanoplatforms for protease detection since I have joined the Bossmann group in 
2012. In 2013, I have begun developing the group of posttranslational sensors, which were 
patented in 2015.  I will give a rationale why the chapter is a part of the thesis at the beginning of 
chapters 2, 3, and 4. 
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Chapter 2 - Early Breast Cancer Screening Using Iron/ Iron Oxide Nanoplatforms with 
Sub-Femtomolar Limits of Detection 
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My research was concerned with determining the influence of the biological matrix (serum) on 
the performance of the nanoplatforms, as well as for the cross-sensitivity of all utilized 
nanoplatforms with respect to each other. Furthermore, in collaboration with Dr. Hongwang 
Wang and Ms. Asanka S. Yapa, I have improved the synthetic procedures of all nanoplatforms 
utilized here.  
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2.1. Abstract 
Proteases, including Matrix Metalloproteinases (MMPs), Tissue Serine Proteases, and 
Cathepsins (CTS) exhibit numerous functions in tumor biology. Solid tumors are characterized 
by changes in protease expression levels by tumor and surrounding tissue. Therefore, monitoring 
protease levels in tissue samples and liquid biopsies is a vital strategy for early cancer detection. 
Water-dispersible Fe/Fe3O4-core/shell based nanoplatforms for protease detection are capable of 
detecting protease activity down to sub-femtomolar limits of detection. They feature one dye 
(tetrakis-carboxyphenyl porphyrin (TCPP)) that is tethered to the central nanoparticle by means 
of a protease-cleavable consensus sequence and a second dye (Cy 5.5) that is directly linked. 
Based on the protease activities of urokinase plasminogen activator (uPA), MMPs 1, 2, 3, 7, 9, 
and 13, as well as CTS B and L, human breast cancer can be detected at stage I by means of a 
simple serum test. By monitoring CTS B and L stage 0 detection may be achieved. This initial 
study, comprised of 46 breast cancer patients and 20 apparently healthy human subjects, 
demonstrates the feasibility of protease-activity-based liquid biopsies for early cancer diagnosis. 
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2.2. Introduction 
We have detected stage I breast cancer in human patients with statistical significance by 
means of a simple serum test using highly sensitive Fe/Fe3O4-nanoparticle based nanoplatforms 
for protease detection. Numerous proteases are required for early mutations, tumor survival, 
progression, angiogenesis, and invasion [1-3]. Following the pioneering research of Weissleder 
et al. [4], molecular [5], macromolecular [6] and nanoparticle-based [7] protease sensors have 
been developed for in-vivo imaging and in-vitro diagnostics of proteases that rely on 
fluorescence and magnetic principles [8]. This technology is characterized by high versatility and 
specificity, because consensus sequences feature high selectivities for the proteases for which 
they were designed [9]. However, the limits of protease detection (LOD’s) of the state-of-the-art 
technology are sub-picomolar (sub-ng/mg) [4-8], which is sufficient for in-vivo imaging of 
tumors [4,8], atherosclerotic  plaques [10] and cardiovascular inflammation [11] in humans and 
in-vivo and in-vitro detection in rodent models for cancers [12,13], but not for the in-vitro 
detection of human cancers [14] in their earliest stages. Competing technologies for quantitative 
protease detection, such as immunosorbent assays [15], quantum dot barcode technology [16], 
and immunobeads [17] have similar LOD’s. Recently Sardar, Korc et al. have reported the 
sensing of short noncoding RNA following a nanoplasmonic approach, which is of similar 
sensitivity and range than the approach reported here [18]. 
We have developed nanoplatforms for protease detection [19, 20] that are capable of 
detecting protease activities over a wide activity range down to sub-femtomolar LOD’s. These 
nanoplatforms consist of dopamine-covered, water-dispersable iron/iron oxide core/shell 
nanoparticles, to which one fluorescent dye (TCPP, tetrakis-carboxyphenyl porphyrin) is tethered 
via a consensus sequence. A second dye (Cyanine 5.5) is permanently linked to the dopamine 
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coating (Figure 2.1). This design enables both, plasmon-resonance quenching (SET) [20, 21] and 
Förster Resonane Energy Transfer (FRET) quenching [20, 22] of the tethered TCPP units. Once 
TCPP is released via proteolytic cleavage of the consensus sequence, its fluorescence will 
increase (for most of the nanoplatforms). 
 
Figure 2.1: Nanosensors for in-vitro protease detection. For each protease, a highly selective 
oligopeptide is used to tether Tetrakis-carboxy-phenyl-porphyrin (TCPP) to the nanoparticle. 
Cyanine 5.5 is linked permanently to the Fe/Fe3O4 nanoparticles. Figure 2.1 is reproduced from 
reference 23 with permission.  
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Figure 2.2: Mechanistic scheme of the “light switch effect” upon proteolytic cleavage: the 
fluorophore is switched on due to the increase in distance between the Fe/Fe3O4 core/shell 
nanoparticle, leading to decreased Förster Energy Transfer (FRET)[21, 24], k1, and dipole-
surface energy transfer (SET)[20,22], k2. Further explanations are provided in the text.  
The nanoplatforms for cancer detection are based on proteolytic cleavage of TCPP from 
the Fe/Fe3O4-core (Figure 2.2). Increasing the distance between the TCPP fluorophore and the 
nanoparticle decreases plasmon-resonance quenching (dipole-surface energy transfer 
(SET)[20,21]) from TCPP to Fe/Fe3O4 and Förster Energy Transfer (FRET[20,22]) from TCPP to 
cyanine 5.5. The latter is permanently tethered to the inorganic nanoparticle. For all of the 
employed consensus sequences, with the exceptions of GAGSGR-SAG for uPA and GAGVPLS-
LYSGAG for MMP 9, an increase in TCPP fluorescence is observed upon enzymatic cleavage. 
This “light switch effect” [20] enables highly sensitive detection of protease activity by 
quantitative fluorescence measurements. In an earlier paper, we have discussed in detail why the 
nanoplatforms for uPA and MMP 9 detection defy the general paradigm: shorter consensus 
sequences and sequences permitting higher dynamics of the attached TCPP lead to fluorescence 
enhancement of the attached fluorophore due to enhanced plasmonic light scattering [24] of the 
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Fe(0) core of the central core/shell nanoparticle. For these specific consensus sequences, this 
effect exceeds the quenching effects (SET and FRET). Therefore, these two nanoplatforms show 
decreases of TCPP fluorescence upon cleavage. However, this decrease can still be utilized to 
measure the activities of uPA and MMP 9 in serum. 
In the US, breast cancer is staged according to the TNM classification system, which is 
based on the extent of the spread of cancer within the body [25]. The overall 5-year survival rates 
for breast cancer are virtually 100% at stages 0 and I, 93% at stage II, 72% at stage III and 22% 
at stage IV [26]. 61% of all breast cancers in the US are diagnosed at combined stages 0 and I, 
32% at stage II and 7% at combined stages III and IV [27]. Since the majority of breast cancer 
mortalities occurs from cases that are detected at stages II and above, detecting breast cancer by 
means of a routine blood test at stage I or earlier would have the potential of significantly 
reducing breast cancer mortality (521,900 globally in 2012)[28]. 
Bhatia et al. proposed nanoscale agents for in-vivo use that are comprised of reporter 
molecules bound via consensus sequences to iron oxide nanoworms. The reporter molecules are 
released in rodent models once the nanoworms have reached the cancer site and then excreted in 
urine. The quantitative detection of the reporter molecules’ concentrations has been achieved by 
paper chromatography [29]. Although this was a major step forward in developing point-of-care 
diagnostics, it is still more than minimally invasive, because the nanoworms have to be given 
intravenously. An ideal “liquid biopsy” [30] will require only the drawing of a simple blood 
sample to detect cancer, without introducing a reagent to the patient’s body first. In this report, 
we would like to discuss this approach. 
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In 2014, we published the synthesis and calibration of Fe/Fe3O4-based nanoplatforms for 
accurate and highly sensitive detection of 12 proteases (Figure 2.1) [20]. The calibration and 
validation experiments were performed with commercially available proteases in PBS 
(phosphate buffered saline, pH=7.4). The average Fe(0) core diameter is 13 ± 0.5nm, the Fe3O4 
shell thickness is 2.0 ± 0.5nm (Figure 2.3). Using statistical modeling, the optimal number of 
TCPP units per nanoparticle was determined to be 35 ± 3, and the number of cyanine 5.5 units to 
be 50 ± 4 [31]. 
 
Figure 2.3: TEM (1a, 1b) and HRTEM (1c) images of Fe/Fe3O4-core/shell nanoparticles that are 
forming the inorganic core of the nanoplatforms for protease detection, with permission of the 
Royal Society of Chemistry [20]. HRTEM images revealed that the Fe(0) centers are mostly 
crystalline (BCC). 
We have obtained serum samples (-80oC) from 46 female breast cancer patients (4 stage 
0, 9 stage I, 9 stage II, 12 stage III and 12 stage IV, as well as 20 healthy human subjects (10 
males and 10 females)) from the Southeastern Nebraska Cancer Center. We have selected serum 
as biospecimen, because at -80oC protease activity is retained for years according to our 
preliminary results. 20 breast cancers were luminal A [32], 12 were luminal B [33], 8 were basal-
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like [32] and 6 were HER2 enriched [32]. All patients (ages 36 to 80) and healthy human 
subjects (ages 26 to 68) were Caucasian. No significant statistical differences in the protease 
expression pattern between the females and males of the control group were found.  
Approximately two percent of the human genome encodes for proteases [34]. Therefore, 
each selection of proteases for a cancer diagnostic panel is somewhat arbitrary. For detecting 
early breast cancer, we have chosen the following proteases: MMPs 1,2,3,7,9,13, uPA and CTS B 
and L. MMP 1 has been associated with telomerase activity and promotion of tumor invasiveness 
and metastatic dissemination [35]. MMPs 2, 7, and 9, as well as other MMPs, release growth 
factors from stromal and epithelial cells at the cancer boundary, cleave off pro-angiogenic factors 
and start pro-angiogenic protease cascades [36, 37]. MMP 13 is involved in the epithelial-
mesenchymal transition [38]. uPA and CTS B facilitate angiogenesis, ECM degradation and 
invasiveness. They also activate growth factors [39, 40]. MMP3 and CTS L are responsible for 
early mutations in carcinogenesis [2, 3]. 
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2.3. Results and Discussion 
In step 1, the influence of the serum matrix on the performance of the nanoplatforms was 
evaluated. For this purpose, we have used combined serum from our control group, which was 
inactivated using established procedures by heating to 56oC for > 30 min [41]. 
 
Figure 2.4: Relative Error from 10 Independently Performed Protease Measurements.  
10 independent repetitions of measuring the activity of the Fe/Fe3O4-nanoplatform for detecting 
MMP13 under standard conditions at 25oC after addition of 1.0 x 10−13mol l−1 of MMP13. The 
relative error was determined to be 3 percent.  
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In short, 3.0 ml of dextran (10 mg dextran in 1.0 ml of PBS) were mixed with 75 μl of the 
nanoplatform dispersion (1.0 mg in 1.0 ml of PBS) and 30 μl of the protease stock solutions at 
each concentration level in a total volume of 3.0 ml of PBS. 30 μl of inactivated serum was 
added before filling up to 3.0 ml when studying matrix effects. The solution was incubated at 
25oC for 60 min. Then the fluorescence was analyzed in 4.0 ml quartz-cuvettes (Helma) using a 
spectrofluorometer (Fluoromax2) with dual monochromators (𝜆ex = 421 nm, 𝜆em = 620-680 nm). 
The complete procedure is described in the Methods Section. From 10 independently performed 
repetitions, we have calculated the experimental error to ± 3% (Figure 2.4). 
The results obtained in the presence and absence of inactivated serum are shown in 
Figures 2.5 and 2.6, as well as in Figure 2.7 (Triangles: fluorescence readings in PBS; Squares: 
fluorescence readings in PBS containing inactivated serum.) 
Most proteases only exhibit moderate matrix effects, because of the very low 
concentration of serum that is required and due to the use of dextran as anti-coagulant [42]. The 
requirement of only a very low volume of serum for performing meaningful enzyme activity 
measurements is a definite advantage of the very high sensitivity of the nanoplatforms for 
protease detection, which originates from the concurrent utilization of SEM and FRET 
quenching. 
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Figure 2.5: Matrix effects for MMP7, MMP13, and cathepsin L after 60 min of incubation at 
25oC under standard conditions. Ip: fluorescence signal after 60 min. of incubation; Ic: 
fluorescence signal in the absence of protease after 60 min. incubation; Is: fluorescence signal of 
serum/PBS-dextran alone. Experimental errors are indicated. 
15 
 
 
 
Figure 2.6: Matrix effects for MMP1, MMP 2, MMP 3, and cathepsin B after 60 min of 
incubation at 25oC under standard conditions. Triangles: fluorescence readings in PBS; Squares: 
fluorescence readings in PBS containing inactivated serum. Ip: fluorescence signal after 60 min. 
of incubation; Ic: fluorescence signal in the absence of protease after 60 min. incubation; Is: 
fluorescence signal of serum/PBS- dextran alone. Experimental errors are indicated. 
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Figure 2.7: Determination of Matrix Effects on the Observed Fluorescence Intensities of the 
Nanoplatforms, Matrix effects for MMP9 and uPA after 60 min of incubation at 25oC under 
standard conditions. Triangles: fluorescence readings in PBS; Squares: fluorescence readings in 
PBS containing inactivated serum. Ip: fluorescence signal after 60 min. of incubation; Ic: 
fluorescence signal in the absence of protease after 60 min. incubation; Is: fluorescence signal of 
serum/PBS-dextran alone. Experimental errors are indicated. A detailed mechanistic discussion 
of the reasons why uPA and MMP9 are defying the “light switch paradigm” is provided in 
reference 2.7. 
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Notable exceptions are MMPs 1 (Figure 2.6) and 7 (Figure 2.5), where significant matrix 
effects were detected. As noted in Table 2.1, the physical properties (isoelectric point and 
hydrophobicity index) of the consensus sequences plus peptide linkers designed for detecting 
MMP 1 and MMP 7 are within the ranges defined by all employed peptide sequences. Pieper et 
al. have analyzed human serum by fractionating serum proteins, followed by two-dimensional 
electrophoresis, and sequential anion-exchange and size-exclusion chromatography. They have 
resolved 3700 posttranslationally modified proteins [43]. Based on their findings, we cannot 
exclude that binding of the peptide sequences designed for MMP 1 and MMP 7 detection to one 
or several serum protein occurs, which is ultimately responsible for the observed photophysical 
behavior of these nanoplatforms. 
Stages     Means    Standard Deviation Average Protease Activity 
in Serum (mol L-1) 
H 1.360853   0.07226045 2.4 x 10-16 
0 1.264777     0.04452960 1.4 x 10-16 
1 1.418908     0.04501105 3.3 x 10-16 
2 2.198153     0.12710588 2.6 x 10-14 
3 2.469330     0.20346940 1.1 x 10-13 
4 3.002602     0.33220471 1.8 x 10-12 
 
Table 2.1: Means, Standard Deviations, and Average Protease Activities in Serum for Cathepsin 
B (CTS B). 
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In Figure 2.7 the results for uPA and MMP9, two proteases that defy the “light switch 
paradigm” are shown. An explanation for this behavior is briefly discussed in the introduction 
section and more thoroughly in reference 20.  
 
2.3.1. Cross-Sensitivities of the Nanoplatforms 
In order to determine the cross-sensitivities of the nanoplatforms, the following control 
experiments were conducted: The nanoplatforms for MMP1,2,3,7,9,13, uPA, and CTS B,L were 
(separately) incubated with 1.0 x 10−10 mol l−1 of MMP1 under standard conditions (see 
Methods). After 60 min. of incubation at 25oC, the fluorescence spectra of all nanoplatforms 
were recorded. The next set of experiments consisted of incubating the nanoplatforms for 
MMP1,2,3,7,9,13, uPA, and CTS B,L with 1.0 x 10−10 mol l−1 of MMP2 under standard 
conditions. This is followed by MMP3, 7, 9, 19, uPA and CTS B, and L. In Figure 2.8, the 
normalized results for this set of experiments are summarized. The normalization procedure 
consists of dividing each set of integrated fluorescence data for each enzyme by the fluorescence 
recording for the correct match in the entire set of nine nanoplatforms. 
Set 1: integrated fluorescence recordings for all nine nanoplatforms incubated with MMP 1 (1.0 
x 10−10 mol l−1), divided by the integrated fluorescence signal obtained with the nanoplatform for 
MMP 1 in the presence of MMP 1; 
Set 2: integrated fluorescence recordings for all nine nanoplatforms incubated with MMP 2 (1.0 
x 10−10 mol l−1), divided by the integrated fluorescence signal obtained with the nanoplatform for 
MMP 2 in the presence of MMP 2; 
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Sets 3 to 8 have been recorded accordingly for MMP 3, 7, 9, 13, uPA and CTS B. 
Set 9: integrated fluorescence recordings for all nine nanoplatforms incubated with CTS L (1.0 x 
10−10 mol l−1), divided by the integrated fluorescence signal obtained with the nanoplatform for 
CTS L in the presence of CTS L. 
 
Figure 2.8: Cross-sensitivities of the nanoplatforms used in this study.  
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2.3.2. Diagnosis of Early Breast Cancer 
The activities of the nine selected proteases in the serum of 46 breast cancer patients and 
20 healthy human subjects were measured following the same procedure as for determining the 
matrix influence, with the exception that active serum was used, and the results statistically 
analyzed. A series of boxplots and bar graphs (Figure 2.9 and Figures 2.10 - 2.18) show the data 
range that correlates to each cancer stage, as well as the protease expression range of healthy 
patients [44]. 
 
Figure 2.9: Bar-graph (left, showing means and standard deviations) and boxplot (right, 
indicating the observed data range) for cathepsin L. The group sizes are H (apparently healthy 
control group, n=20), 0: breast cancer stage 0 (+ 
n=4), 1: breast cancer stage 1 (n=9), 2: breast cancer stage 2 (n=9), 3: breast cancer stage 3 
(n=12); 4: breast cancer stage 4 (n=12). All biospecimens were obtained from the South Eastern 
Nebraska Cancer Center (SNCC). Breast cancer has been staged according to the TNM staging 
system [25]. 
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Figure 2.10: Boxplot and Bar-Graph for Cathepsin B  
Bar-graph (left, showing means and standard deviations) and boxplot (right, indicating the 
observed data range) for cathepsin B. The group sizes are H (apparently healthy control group, 
n=20), 0: breast cancer stage 0 (n=4), 1: breast cancer stage 1 (n=9), 2: breast cancer stage 2 
(n=9), 3: breast cancer stage 3 (n=12); 4: breast cancer stage 4 (n=12). All biospecimens were 
obtained from the Southeastern Nebraska Cancer Center (SNCC). Breast cancer has been staged 
according to the TNM staging system.2.7 
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Figure 2.11: Boxplot and Bar-Graph for Cathepsin L  
Bar-graph (left, showing means and standard deviations) and boxplot (right, indicating the 
observed data range) for cathepsin L. The group sizes are H (apparently healthy control group, 
n=20), 0: breast cancer stage 0 (n=4), 1: breast cancer stage 1 (n=9), 2: breast cancer stage 2 
(n=9), 3: breast cancer stage 3 (n=12); 4: breast cancer stage 4 (n=12). All biospecimens were 
obtained from the South Eastern Nebraska Cancer Center (SNCC). Breast cancer has been staged 
according to the TNM staging system.2.7 
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Stages     Means    Standard Deviation Average Protease Activity 
in Serum (mol L-1) 
H 1.923536     0.40659660 1.8 x 10-15 
0 2.245194     0.09365240 8.5 x 10-15 
1 2.243285     0.04673341 8.4 x 10-15 
2 2.312233     0.18165558 1.1 x 10-14 
3 2.790727     0.29286377 5.4 x 10-14 
4 3.021944     0.25981286 1.2 x 10-13 
 
Table 2.2: Means, Standard Deviations, and Average Protease Activities in Serum for Cathepsin 
L (CTS L) 
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Figure 2.12: Boxplot and Bar-Graph for Urokinase Plasminogen Activator  
Bar-graph (left, showing means and standard deviations) and boxplot (right, indicating the 
observed data range) for urokinase plasminogen activator (uPA). The group sizes are H 
(apparently healthy control group, n=20), 0: breast cancer stage 0 (n=4), 1: breast cancer stage 1 
(n=9), 2: breast cancer stage 2 (n=9), 3: breast cancer stage 3 (n=12); 4: breast cancer stage 4 
(n=12). All biospecimens were obtained from the South Eastern Nebraska Cancer Center 
(SNCC). Breast cancer has been staged according to the TNM staging system.2.7 
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Stages     Means    Standard Deviation Average Protease 
Activity in Serum (mol 
L-1) 
H 0.9848335       0.025264087 1.3 x 10-15 
0 0.9900917     0.005991484 7.8 x 10-16 
1 0.9034983     0.022280082 2.1 x 10-12 
2 0.8860111     0.015128888 1.0 x 10-11 
3 0.8832422     0.015965042 1.3 x 10-11 
4 0.8741700       0.014332318 2.0 x 10-11 
 
Table 2.3: Means, Standard Deviations, and Average Protease Activities in Serum for Urokinase 
Plasminogen Activator (uPA). 
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Figure 2.13: Boxplot and Bar-Graph for MMP 1  
Bar-graph (left, showing means and standard deviations) and boxplot (right, indicating the 
observed data range) for matrix metalloproteinase 1 (MMP 1). The group sizes are H (apparently 
healthy control group, n=20), 0: breast cancer stage 0 (n=4), 1: breast cancer stage 1 (n=9), 2: 
breast cancer stage 2 (n=9), 3: breast cancer stage 3 (n=12); 4: breast cancer stage 4 (n=12). All 
biospecimens were obtained from the South Eastern Nebraska Cancer Center (SNCC). Breast 
cancer has been staged according to the TNM staging system.2.7 
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Stages     Means    Standard Deviation Average Protease 
Activity in Serum (mol 
L-1) 
H 1.314616     0.23507424 1.6 x 10-15 
0 1.236894     0.03339194 5.9 x 10-16 
1 1.978331     0.04220099 7.8 x 10-12 
2 1.995024     0.10799028 9.6 x 10-12 
3 2.210357     0.21628141 1.5 x 10-10 
4 2.292405     0.39496657 4.3 x 10-10 
 
Table 2.4: Means, Standard Deviations, and Average Protease Activities in Serum for Matrix 
Metalloproteinase 1 (MMP 1) 
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Figure 2.14: Boxplot and Bar-Graph for MMP 2 
Bar-graph (left, showing means and standard deviations) and boxplot (right, indicating the 
observed data range) for matrix metalloproteinase 2 (MMP 2). The group sizes are H (apparently 
healthy control group, n=20), 0: breast cancer stage 0 (n=4), 1: breast cancer stage 1 (n=9), 2: 
breast cancer stage 2 (n=9), 3: breast cancer stage 3 (n=12); 4: breast cancer stage 4 (n=12). All 
biospecimens were obtained from the South Eastern Nebraska Cancer Center (SNCC). Breast 
cancer has been staged according to the TNM staging system.2.7 
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Stages     Means    Standard Deviation Average Protease 
Activity in Serum (mol 
L-1) 
H 1.551050     0.2210302 4.0 x 10-15 
0 1.381780     0.2078706 6.4 x 10-16 
1 2.093351     0.2287855 1.4 x 10-12 
2 2.181590     0.2301482 3.6 x 10-12 
3 2.616193     0.4300199 4.0 x 10-10 
4 2.200369     0.3192078 4.4 x 10-12 
 
Table 2.5: Means, Standard Deviations, and Average Protease Activities in Serum for Matrix 
Metalloproteinase 2 (MMP 2) 
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Figure 2.15: Boxplot and Bar-Graph for MMP 3  
Bar-graph (left, showing means and standard deviations) and boxplot (right, indicating the 
observed data range) for matrix metalloproteinase 3 (MMP 3). The group sizes are H (apparently 
healthy control group, n=20), 0: breast cancer stage 0 (n=4), 1: breast cancer stage 1 (n=9), 2: 
breast cancer stage 2 (n=9), 3: breast cancer stage 3 (n=12); 4: breast cancer stage 4 (n=12). All 
biospecimens were obtained from the South Eastern Nebraska Cancer Center (SNCC). Breast 
cancer has been staged according to the TNM staging system.2.7 
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Stages     Means    Standard Deviation Average Protease Activity 
in Serum (mol L-1) 
H 1.276774        0.10293781 3.4 x 10-16 
0 1.248445     0.05253079 2.2 x 10-16 
1 1.361347     0.02882905 1.2 x 10-15 
2 1.423178     0.13355403 2.9 x 10-15 
3 1.383381     0.12401589 1.6 x 10-15 
4 1.670680     0.13369459 1.2 x 10-13 
 
Table 2.6: Means, Standard Deviations, and Average Protease Activities in Serum for Matrix 
Metalloproteinase 3 (MMP 3) 
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Figure 2.16: Boxplot and Bar-Graph for MMP 7  
Bar-graph (left, showing means and standard deviations) and boxplot (right, indicating the 
observed data range) for matrix metalloproteinase 7 (MMP 7). The group sizes are H (apparently 
healthy control group, n=20), 0: breast cancer stage 0 (n=4), 1: breast cancer stage 1 (n=9), 2: 
breast cancer stage 2 (n=9), 3: breast cancer stage 3 (n=12); 4: breast cancer stage 4 (n=12). All 
biospecimens were obtained from the South Eastern Nebraska Cancer Center (SNCC). Breast 
cancer has been staged according to the TNM staging system.2.7 
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Stages     Means    Standard Deviation Average Protease 
Activity in Serum (mol 
L-1) 
H 1.265858     0.08413963 6.4 x 10-16 
0 1.235173     0.09279042 4.5 x 10-16 
1 1.276960     0.08834555 7.2 x 10-16 
2 1.306292     0.09032285 1.0 x 10-15 
3 1.384025     0.14060255 2.5 x 10-15 
4 1.349619     0.12004177 1.7 x 10-15 
 
Table 2.7: Means, Standard Deviations, and Average Protease Activities in Serum for Matrix 
Metalloproteinase 7 (MMP 7) 
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Figure 2.17: Boxplot and Bar-Graph for MMP 9  
Bar-graph (left, showing means and standard deviations) and boxplot (right, indicating the 
observed data range) for matrix metalloproteinase 9 (MMP 9). The group sizes are H (apparently 
healthy control group, n=20), 0: breast cancer stage 0 (n=4), 1: breast cancer stage 1 (n=9), 2: 
breast cancer stage 2 (n=9), 3: breast cancer stage 3 (n=12); 4: breast cancer stage 4 (n=12). All 
biospecimens were obtained from the South Eastern Nebraska Cancer Center (SNCC). Breast 
cancer has been staged according to the TNM staging system.2.7 
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Stages     Means    Standard Deviation Average Protease Activity 
in Serum (mol L-1) 
H 0.9622952     0.011980785 8.6 x 10-13 
0 0.9507300     0.010709674 5.9 x 10-12 
1 0.9530756     0.006783337 4.0 x 10-12 
2 0.9439189     0.014798504 1.8 x 10-11 
3 0.9308592     0.005204805 1.6 x 10-10 
4 0.9327775     0.009121815 1.2 x 10-10 
 
Table 2.8: Means, Standard Deviations, and Average Protease Activities in Serum for Matrix 
Metalloproteinase 9 (MMP 9) 
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Figure 2.18: Boxplot and Bar-Graphs for MMP 13  
Bar-graph (left, showing means and standard deviations) and boxplot (right, indicating the 
observed data range) for matrix metalloproteinase 13 (MMP 13). The group sizes are H 
(apparently healthy control group, n=20), 0: breast cancer stage 0 (n=4), 1: breast cancer stage 1 
(n=9), 2: breast cancer stage 2 (n=9), 3: breast cancer stage 3 (n=12); 4: breast cancer stage 4 
(n=12). All biospecimens were obtained from the South Eastern Nebraska Cancer Center 
(SNCC). Breast cancer has been staged according to the TNM staging system.2.7 
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Stages     Means    Standard Deviation Average Protease Activity 
in Serum (mol L-1) 
H 2.402871     0.6767673 3.2 x 10-15 
0 2.454853     0.6726423 3.7 x 10-15 
1 2.447914     0.5209525 3.6 x 10-15 
2 2.483194     0.6442519 4.0 x 10-15 
3 2.453076     0.9055961 3.7 x 10-15 
4 2.701158     1.0781773 7.5 x 10-15 
 
Table 2.9: Means, Standard Deviations, and Average Protease Activities in Serum for Matrix 
Metalloproteinase 13 (MMP 13) 
 
The analyzed enzymes include Cathepsin B and L, MMP 1, 2, 3, 7, 9, 13 and uPA. Except 
for MMP9 and uPA, all enzymes display a positive trend with an increasing signal for higher 
cancer stages. The reason for this behavior is discussed in the text: in short, the nanoplatforms 
for uPA and MMP 9 detection show decreasing fluorescence intensities with increasing protease 
activity. We have chosen boxplots and bar-graphs for data analysis, in combination with Welch 
two sample t-tests (control group and cancer patients at a defined stage) [45], because a 
combination of these analysis methods provides a simple system for data analysis. The boxplots 
show the data range that correlates to a certain cancer stage while the bar graphs display the 
average signal and standard deviation (represented by the error bar) for individual cancer stages. 
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With respect to detecting cancer at an early stage, the data obtained for cathepsin B and L, uPA 
and MMP 1, 3 and 9 is superior to MMP 2, 7 and 13. Here the fluorescence signals for each 
cancer stage are compared with the healthy control group’s fluorescence signals. Highly 
significant differences between cancer patients and healthy control group are achieved with 
cathepsins B and L, uPA, MMP1 and 9. It is noteworthy that only cathepsins B and L are 
significantly different from the healthy group for stage 0 breast cancer. Especially cathepsin L 
seems promising here since it maintains its positive trend of the signal. However, the stage 0 
group is very small (n=4). Therefore, all enzymes should be revisited when more data becomes 
available.  
Highly significant differences are achieved with CTS B, L, uPA, MMP 1 and 9. It is 
interesting to observe that only CTS B and L produce a signal for stage 0 breast cancer that is 
significantly different from the healthy group. Especially CTS L seems promising here since it 
maintains its positive trend of the signal. However, the stage 0 group is too small (n=4) and the 
control group is somewhat spread out. Stage 0 has to be revisited when more data becomes 
available. 
In Figure 2.19, the calculated p-values [45] obtained for comparisons of the protease 
expression pattern in each cancer stage with those of the healthy control group are tabulated, 
leading to the “Significance Table”. The color green denotes for measured fluorescence signals 
that are significantly enhanced (p < 0.05) in cancer patients compared to the healthy control 
group. The color yellow represents findings, in which the fluorescence signals detected in the 
serum of cancer patients were significantly smaller than in the control group. The color red was 
used for all cases in which significant results could not be obtained. It should be noted (again) 
39 
 
that uPA and MMP 9 are the “defiant proteases”. Their fluorescence signals decrease with 
increased protease activity. 
 
 
Figure 2.19: Calculated p-values; comparison of breast cancer patients and healthy human 
subjects for all investigated enzymes, stages 0-4 - Green: fluorescence signal (FS) of cancer 
patients is significantly larger than of control group (CG); Yellow: FS is significantly smaller; 
Red: differences in FS and CG are not significant. 
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The resulting average enzyme activities in the serum of the healthy control group and 
breast cancer stages 0, 1, 2, 3, and 4 are summarized in Figure 2.20.  
 
Figure 2.20: Average protease activity as a function of breast cancer stage / healthy control group 
for all nine proteases monitored in this study. Note that the activity is shown on a logarithmic 
scale (log10 (protease activity)). The data summarized in this figure is also reported in Tables 2.1 
to 2.9. 
 
Healthy control groups and stages are color coded. From this plot, it can be discerned 
why cathepsin L is the best enzyme to detect both, early breast cancer and cancer staging. MMP 
1, MMP 9 and uPA show similar enzyme activity trends, but we were unable to distinguish 
between healthy patients and stage 0 breast cancer patients. The inability to reach this goal was 
due to variations of protease expression among the apparently healthy human subjects and the 
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small sample size (n=4) in stage 0. Cathepsin B, MMP 2 can be used to identify breast cancer 
patients that are in or beyond stage 2. MMP 3 could, in theory, identify late stage patients. 
Finally, MMP 7 and MMP 13 did not yield conclusive results. It is noteworthy that although 
MMP 2, 7, and 9 belong to a group of MMPs that are known to release are known to release 
growth factors, cleave off pro-angiogenic factors and start pro-angiogenic protease 
cascades[36,37], MMP 2 and MMP 9 yield conclusive results for stages one to four, whereas 
MMP 7 is only conclusive at higher stages. MMP 13 did not generate any significant results, 
although MMP 13 is involved in the epithelial-mesenchymal transition [38]. The reasons for 
these deviations among related matrix metalloproteinases may be found in different tissue 
retention and enzymatic degradation of individual proteases, as well as in the activity profiles of 
tissue inhibitors of metalloproteinases (TIMPs) in blood [46]. 
 
 
2.4. Conclusion 
In conclusion, the most important result of this research is that we are able to detect 
breast cancer at stage I monitoring seven proteases and at stage 0 observing one protease with 
high statistical significance. This result is of importance, because we have achieved it with 
relatively small group sizes of breast cancer patients and healthy control subjects. As always 
when testing biomarkers, the selection process of the required biospecimens is crucial. 
Therefore, our next steps will consist in testing our liquid biopsy approach with significantly 
larger group sizes of stage 0 and I breast cancer patients.  
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2.5. Methods 
2.5.1. Synthesis of core/ shell iron/ iron oxide - Fe/Fe3O4 nanoparticles 
The synthesis of dopamine-coated nanoparticles (Figure 2.21) has been established in the 
Bossmann group by performing a modification of a literature procedure depicted by Lacroix et 
al. The published synthesis procedure Wang et al. (2014) was followed for this research20. 
 
Figure 2.21: Synthesis of core/ shell iron/ iron oxide - Fe/Fe3O4 nanoparticles (Wang et al. 
2012) 
The synthesis procedure (from Wang et al. (2014)) is reproduced here. A 250 mL, three-
necked, round-bottom flask equipped with a magnetic stir bar, one cold water cooled jacket 
condenser on the middle neck, one septum and one temperature probe on each of the outer necks 
was charged with 60 mL 1-octadecene (ODE), 0.9 mL oleylamine and 0.831 g 
hexadecylammonium chloride (HADxHCl). The reaction system was connected to a Schlenk line 
through the top of the jacket condenser. The reaction mixture was degassed at 120oC for 30 min 
with vigorous stirring. After being refilled with argon, the reaction mixture was heated to 180o 
C. Three portions of 0.7 mL Fe(CO)5 were injected into the reaction mixture via syringe, every 
20 min. The reaction mixture was kept at 180o C for another 20 min after the last injection, and 
then cooled to room temperature naturally. The supernatant was decanted, and the iron 
nanoparticles accumulated on the magnetic stir bar were washed with hexane and ethanol. The 
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product was dried in vacuum and stored at room temperature under argon for further use. Based 
on the iron content of the nanoparticles, which was determined spectrophotometrically after 
dissolving the nanoparticles in aqueous HCl (1.0 M) and subsequent complexation with ferrozine 
(sodium 4,4'-(3-(pyridin-2-yl)-1,2,4-triazine-5,6-diyl)dibenzenesulfonate)2 , the yield of the 
reaction is 95%. 
 
2.5.2. Dopamine coating of the core/ shell iron/ iron oxide nanoparticles. 
The Fe/Fe3O4-nanoparticles will be protected by using dopamine. The synthesis 
procedure (from Wang et al. (2014)) is reproduced here. 
Dopamine Coating of the core/shell Fe/Fe3O4 Nanoparticles 0.50 g of previously 
synthesized Fe/Fe3O4 nanoparticles was dispersed in 100 mL chloroform via sonication. With 
vigorous mechanical stirring, a solution of 0.50 g dopamine-hydrochloride in 50 mL chloroform 
was added drop-wise to the nanoparticle suspension. The reaction mixture was further stirred at 
room temperature for 24 hours, and then the dopamine coated nanoparticles were collected by 
centrifugation. After washing with chloroform 5 times, nanoparticles were dried under vacuum. 
0.47 g dopamine coated Fe/Fe3O4 nanoparticles were collected 20. 
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2.5.3. Synthesis of TCPP Fluorophore 
The synthesis of (4-carboxyphenyl)porphyrin has been established in the Bossmann 
group by performing a variation of a literature procedure of Pereira et al. (2008)51.  
 
Figure 2.22: Reaction scheme for synthesis of TCPP 
The published synthesis procedure (from Wang et al. (2014)) was followed for this 
research. 1.50 g 4-carboxybenzaldehyde was dissolved in 80 mL acetic acid. The solution was 
warmed to 100oC and a solution of 0.67 g pyrrole in 10 mL acetic acid was added dropwise over 
20 minutes. Upon completion of addition, the solution was warmed to 120 oC slowly and was 
kept at 120 oC for 1 hour (Figure 2.22). The mixture was cooled to 80o C and 100 mL 95% 
ethanol was added and then lowered to room temperature, while stirring in 3 hours. Then the 
mixture was kept in at -15 oC for 24 hours. Purple solid was collected by vacuum filtration. The 
filter cake was washed with cold 50/50 ethanol/acetic acid (3×5mL) and dried under high 
vacuum (oil pump) overnight. 0.51g of pure product was obtained (25.5% yield) 20. 1H NMR 
(DMSO-d6) δ: -2.94 (s, 2H); 8.35 (d, 8H); 8.39 (d, 8H); 8.86 (s, 8H); 13.31 (s, 4H) (Figure A1) 
13C NMR (DMSO-d6) δ: 119.31; 127.90; 130.51; 134.44; 145.42; 167.46. MS-ESI+: m/z 791.2. 
Molecular weight calculated as 790.2 (Figure A2). 
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2.5.4. Synthesis of Cyanine 5.5 
The fluorescent cyanine 5.5 dye was synthesized following three reaction schemes. 
Reaction procedures are variation of literature procedures described in Carreon et al. (2007)52. 
The published synthesis procedures (from Wang et al. (2014)) was followed for this research 20. 
 
2.5.4(A) Synthesis of 4-(1,1,2-trimethyl-1H-benzo[e]indol-3-ium-3-yl)butane-1-sulfonate 
(Figure 2.23) 
The published synthesis procedure (from Wang et al. (2014)), which is an alteration of the 
synthetic procedure in Carreon et al. (2007) was followed. 
 
Figure 2.23: Reaction scheme for synthesis of 4-(1,1,2-trimethyl-1H-benzo[e]indol-3-ium-3-
yl)butane-1-sulfonate. 
  
A 50 mL two necked round bottom flask fitted with a magnetic stirrer and a condenser was flame 
dried. 1,1,2-trimethyl-1H-benzo[e]indole (1.0g, 4.78mmol) was dissolved in dry o-
dichlorobenzene (10 mL). 1, 4-butanesultone (0.58mL, 5.73mmol) was added drop-wise under a 
continuous flow of argon. The reaction mixture was, then, allowed to heat up to 130 0C for 24h. 
The reaction mixture was allowed to cool down to room temperature to obtain a blue colored 
precipitate. The precipitate was triturated with ice-cold diethyl ether (40mL) for 15min. The 
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precipitate was filtered through frit glass, washed with cold diethyl ether (3 x 5mL), dried in 
vacuum yielding 4-(1,1,2-trimethyl-1H-benzo[e]indol-3-ium-3-yl)butane-1-sulfonate. 
 
2.5.4(B) Synthesis of 3-(5-carboxypentyl)-1,1,2-trimethyl-1H-benzo[e]indol-3-ium (Figure 
2.24) 
The published synthesis procedure (from Wang et al. (2014)), which is an alteration of 
the synthetic procedure in Carreon et al. (2007) will be followed.  
 
Figure 2.24: Reaction scheme for synthesis of 3-(5-carboxypentyl)-1,1,2-trimethyl-1H-
benzo[e]indol-3-ium. 
A two-necked 50 mL round bottom flask fitted with reflux condenser and stirring bar was be 
charged with 1,1,2-trimethyl-1H-benzo[e]indole, (1.0g, 4.78mmol) which was flushed with 
argon three times. After dissolving in dry o-dichlorobenzene (15 mL), (0.93g, 4.78mmol) of 6-
bromohexanoic acid was added. The reaction mixture was stirred for 36h at 120 oC by using an 
oil bath. This will result in a dark blue solution. The reaction mixture was allowed to cool down 
to room temperature. This cooled solution was triturated with 1:1 diethyl ether and hexane 
mixture (total volume 90 mL) for an hour. The blue precipitate will be filtered off, washed with 
diethyl ether (3 x 20mL) and dried in vacuum yielding 3-(5-carboxypentyl)-1,1,2-trimethyl-1H-
benzo[e]indol-3-ium. 
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2.5.4(C) Synthesis of Cyanine 5.5 (4-(2-((1E,3E,5E)-5-(3-(5-carboxypentyl)-1,1-dimethyl-
1H-benzo[e]indol-2(3H)-ylidene)penta-1,3-dien-1-yl)-1,1-dimethyl-1H-benzo[e]indol-3-ium-
3-yl)butane-1-sulfonate, bromide salt) ( Figure 2.25) 
 The published synthesis procedure (from Wang et al. (2014)), which is an alteration of 
the synthetic procedure in Carreon et al. (2007), was followed. 
A 50mL two-necked oven dry round bottom flask fitted with a magnetic stir bar was 
flushed with argon. Indolium salt, 1 (0.1g, 0.29 mmol) and malondialdehyde bis(phenylimine) 
monohydrochloride 2 (0.09g, 0.35mmol) were charged into the 50mL round bottom flask. Acetic 
anhydride (10mL) was added to this mixture and slowly heated to 120 oC in an oil bath and the 
reaction was monitored through TLC. The reaction was allowed to remain at 120 oC for half an 
hour. The reaction was then cooled to room temperature. An indolium salt, 3 (0.175g, 
0.433mmol) in dry pyridine (5mL) was added to the above reaction dropwise. The reaction was 
allowed to stir at room temperature for 16h. The mixture was, then, concentrated in a rotavap and 
the residue was dissolved in CH2Cl2 (3mL) and loaded on silica column chromatography with 
CH2Cl2: MeOH solvent system (total volume = 2L). A gradient of 100% to 25% of solvent 
CH2Cl2 was used to obtain 0.21g of a deep blue colored dye. Percentage yield of cyanine 5.5: 
92%. 1H NMR (DMSO-d6, 400 MHz) δ (ppm): 8.48 (t, J=12Hz, 2H), 8.24(d, J=8.2Hz, 2H), 
8.06(m, 2H), 7.78(m, 1H), 7.67(m, 1H), 7.51(m, 2H), 6.65(dd, J=8Hz, 1H), 6.44(d, J=12Hz, 1H), 
6.33(d, J=12Hz, 1H), 4.23(m, 4H), 3.0(m, 2H), 2.08(m, 2H), 1.96(m, 2H), 1.78(s, 16H), 1.57(m, 
2H), 1.42(m, 2H). 
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Figure 2.25: Reaction scheme for synthesis of Cyanine 5.5 (4-(2-((1E,3E,5E)-5-(3-(5-
carboxypentyl)-1,1-dimethyl-1H-benzo[e]indol-2(3H)-ylidene)penta-1,3-dien-1-yl)-1,1-
dimethyl-1H-benzo[e]indol-3-ium-3-yl)butane-1-sulfonate, bromide salt)  
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2.5.5. Peptide synthesis 
The oligopeptides used as consensus sequences, which were synthesized in the Bossmann group 
by means of solid-supported peptide synthesis [20], are summarized in Table 2.1. Trityl-resin 
was used as a matrix polymer solid support. Peptide synthesis can be completed in the same 
peptide synthesis tube by the repetitive steps in addition of specific amino acid, filtration and 
washings, accordingly. Commercially available N-terminal protected C-terminal amino acids 
were used for the synthesis53. 
Protease Consensus Sequence Isoelectric Point 
(pI) 
Hydrophobicity 
Index at pH=6.8 
MMP1 GAGVPMS-MRGGAG 11.18 18.54 
MMP2 GAGIPVS-LRSGAG 11.18 22.08 
MMP3 GAGRPFS-MIMGAG 11.18 27.77 
MMP7 GAGVPLS-LTMGAG 6.09 30.31 
MMP9 GAGVPLS-LYSGAG 6.0 28.08 
MMP13 GAGPQGLA-GQRGIVAG 11.18 19.88 
uPA GAGSGR-SAG 11.18 22.08 
Cathepsin (CTS) B GAGSLLKSR-MVPNFNAG 11.6 20.82 
Cathepsin (CTS) L GAGSGVVIA-TVIVITAG 6.09 43.82 
Table 2.10: Consensus sequences in single-letter code for 9 proteases. Essential amino acids of 
the consensus sequences are bold. (http://www.lifetein.com/peptide-analysis-tool.html) 
50 
 
The resin was preloaded into the peptide synthesis tube and swelled in dichloromethane 
(DCM) for 20 minutes and then filtered. DCM was washed away by five consecutive of N,N-
Dimethylformamide (DMF) washings. A mixture of Fmoc protected amino acid and O-
Benzotriazole-N,N,N',N'tetramethyl-uronium-hexafluoro-phosphate (HBTU) as coupling agent 
were added, swirled 30 minutes, and then filtered. This step was repeated once. Excess amino 
acid and the coupling agent were washed away by five DMF washings. Then 20% piperidine in 
DMF was used for N-deprotection. Subsequent amino acid coupling was performed after N-
deprotection. The oligopeptides used as consensus sequence were synthesized using amino acid 
by amino acid from C-terminus to N-terminus53. The peptide synthesis process is schematically 
represented in Figure 2.26. 
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Figure 2.26: Schematic representation of solid phase peptide synthesis process 
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2.5.6. Coupling of TCPP to the Oligopeptide Consensus Sequences 
TCPP is connected to the N-terminal of the oligopeptides while it was still on the resin, 
following same coupling conditions as for an amino acid. 
Finally, the TCPP conjugated oligopeptide was then cleaved off the resin and also the side chain 
protecting groups were removed using a mixture of TFA, TIPS and water (95: 2.5 : 2.5). TCPP- 
oligopeptide was precipitated in cold ether and collected by centrifuging at 10000rpm. After 
precipitation, several DMF washings were carried out to remove the excess of unreacted TCPP 
and other reagents. Three final ether washings were carried out, in order to remove leftover 
DMF. 
 
2.5.7. Nanoplatform Synthesis 
The published synthesis procedure (from Wang et al. (2014), is reproduced here. 200 mg 
of dopamine coated Fe/Fe3O4 nanoparticles were dispersed in 5 mL of DMF. 200 mg of 
dopamine coated Fe/Fe3O4 nanoparticles were dispersed in 5 mL of DMF. A solution of 3 mmol 
of Cy5.5, 3.3 mmol of EDC, 1 mmol of DMAP in 1 mL of DMF was added to this dispersion. 
After sonicating for 1 h, the nanoparticles were precipitated by a magnet, and thoroughly washed 
with DMF (1 mL × 10). The TCPP-oligopeptide was linked to the primary amine groups of 
Fe/Fe3O4-bound via an amide bond [20]. Note that these sequences also contain GAG and AG as 
peptide linkers. The recovered nanoparticles were redispersed in 5 mL of DMF, and to this 
dispersion, 2 mmol of TCPP linked peptide sequence, 2.2 mmol of EDC, 1 mmol of DMAP in 2 
mL of DMF were added. After sonicating for 1 h, the nanoparticles were precipitated by a 
magnet (0.55T), and thoroughly washed with DMF (1 mL × 10). After drying in high vacuum, 
170-185 mg of nanoplatform can be obtained. The composition of the nanoplatform was 
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analyzed by means of UV-Vis spectroscopy (Agilent HP 8543A). After combining all washing 
fractions and subsequent solvent removal in high (682nm) = 5.17) were taken up in 1.0 ml 
methanol and quantitatively measured taking advantage of their high absorption coefficients. The 
nanoplatforms were dispersed in PBS, and TCPP and cyanine 5.5 were measured by UV/Vis-
spectroscopy as well, using dopamine coated Fe/Fe3O4-nanoparticles in PBS as the reference. 
The iron-content of the nanoplatforms was independently determined using the ferrozine assay.2 
This resulting data, together with the size of the Fe/Fe3O4-nanoparticles, enables the calculation 
of the average ratio of TCPP and cyanine 5.5 per nanoparticle. 
 
 
2.5.8. Standard procedure of preparing protease assays (without serum) 
3.0 mg of nanoplatform were dissolved in 3.0 ml of PBS. The dispersion was sonicated 
for 10 min. The resulting dispersion is chemically stable for 14 days at 4oC. 900 mg of dextran 
were dissolved in 90 ml of PBS. Stock solutions of all 9 enzymes were prepared by consecutive 
dilution of commercially available proteases (Enzo Lifesciences). 3 ml of PBS–dextran (10 mg 
dextran in 1.0 ml of PBS) are mixed with 75 μl of the nanoplatform dispersion (3.0 mg in 3.0 ml 
of PBS, see above) and 30 μl of each of the proteases at every concentration level in PBS. The 
dispersions were incubated at 25oC for 60min, followed by the recording of a fluorescence 
spectrum at 25oC using a Fluoromax2 spectrometer (λem = 421nm, λex = 620 – 680nm). 
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2.5.9. Standard procedure of preparing protease assays (with inactivated serum) 
3.0 mg of nanoplatform were dissolved in 3.0 ml of PBS. The dispersion was sonicated 
for 10 min. The resulting dispersion is chemically stable for 14 days at 277 K. 900 mg of dextran 
were dissolved in 90 ml of PBS. Stock solutions of all 9 enzymes were prepared by consecutive 
dilution of commercially available proteases (Enzo Lifesciences). 3 ml of PBS–dextran (10 mg 
dextran in 1.0 ml of PBS) are mixed with 75 μl of the nanoplatform dispersion (3.0 mg in 3.0 ml 
of PBS, see above), 30 μl of inactivated serum, and 30 μl of each of the proteases at every 
concentration level in PBS. The dispersions were incubated at 25oC for 60min., followed by the 
recording of a fluorescence spectrum at 25oC using a Fluoromax2 spectrometer (λex = 421nm, 
λem = 620 – 680nm). Inactivation of serum was achieved by heating to 56oC in an incubator for 
45min., taking the heating time of the serum from RT to the chosen temperature into account, 
making sure that the serum is heated for a minimum of 30min. Inactivated serum tested negative 
with all nine nanoplatforms for protease measurements employed in this study. 
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Chapter 3 - Nanoplatforms for the Detection of Arginase 
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3.1. Abstract 
The enzyme arginase, which is overexpressed in many solid tumors, is able to degrade 
the amino acid arginine.  L-arginine deficiency is resulting in an impaired immune system. Two 
nanoplatforms for arginase detection were designed and synthesized.  Both feature a central 
dopamine-coated iron/iron oxide nanoparticle to which sulfonated cyanine 7.0 or cyanine 7.5 is 
tethered via stable amide bonds.  In both nanoplatforms, cyanine 5.5 is linked to the N-terminal 
of the peptide sequence GRRRRRRRG.  Arginine (R) reacts to ornithine (O) in the presence of 
arginase II. This chemical transformation occurs without proteolytic cleavage of the 
oligopeptide. This is the first example for the “posttranslational sensor”, which permits detection 
of arginase within an hour. It is noteworthy that the nanoplatforms for arginase detection do not 
show a fluorescence increase when incubated with the enzyme NO-reductase, which also uses 
arginase as substrate, but is indicative of an immune response by the host to cancer and 
infections. The arginase activity was determined in a syngeneic mouse model for aggressive 
breast cancer (4T1 tumors in BALB/c mice). It was found that the arginase activity is 
systemically enhanced, but especially pronounced in the active tumor regions.   
 
Keywords: Posttranslational sensor, arginase detection, iron/iron oxide nanoparticle-based 
nanoplatform, fluorescence detection 
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3.2. Introduction 
 
Arginase metabolizes L-arginine to L-ornithine and urea [1]. Besides its fundamental role 
in the hepatic urea cycle, arginase is a key player in the immune system. In humans, arginase I is 
constitutively expressed in polymorphonuclear neutrophils, released during inflammation and 
responsible for the down-regulation of nitric oxide synthesis by converting arginine to ornithine. 
Arginase-mediated L-arginine depletion is capable of suppressing T cell immune responses, 
leading to inflammation-associated immune-suppression, which is a hallmark of aggressive solid 
tumors [2]. Furthermore, L-arginine insufficiency is also responsible for dysfunction of natural 
killer (NK) cells, which are vital for early host defense against infections and tumors [3].  
Arginase can be found in mammalian bodies in two isoforms: arginase I and arginase II. 
Whereas arginase I is (mainly) a liver enzyme [4], arginase II can be found, in varying 
concentrations, in tissue [5]. Arginase I has been recognized as a biomarker for pancreatic 
adenocarcinoma [6]. Arginase II is expressed in cancer-associated fibroblasts and indicates tissue 
hypoxia and predicts poor outcome in patients with pancreatic cancer [7].  However, since fast, 
reliable and sensitive plate reader tests for arginase detection are not available to date, numerous 
potential other applications for this technology can be envisioned [8]. Colorimetric arginase tests 
kits are commercially available. The most sensitive test to data has a limit of detection (LOD) of 
2 x 10-7 moles L-1[9]. In this UV/Vis-absorption-based assay, arginase reacts with arginine and 
undergoes a series of reactions to form a colored product (λmax= 570 nm). The aim of this 
endeavor is to design a fluorescence-based arginase sensor that is equally sensitive as the 
technically more complex immunoassays (target LOD: sub-picomolar) [10]. 
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Figure 3.1: X-ray structure of Arginase II (1PQ3) 
(http://www.rcsb.org/pdb/pv/pv.do?pdbid=1PQ3&bionumber=1, accessed on 02/12/2016). 
 
Arginases I and II belong to the family of ureohydrolases. Mammalian arginase II is active as a 
trimer [11]. It requires a manganese cluster to maintain its function. Mn2+ coordinates and 
activates H2O, thus enabling it to act as effective nucleophile. It is noteworthy that arginase II, 
contrary to NO-reductase, is not only able to transform free arginine to ornithine, but to catalyze 
the same reaction if arginine is part of am oligopeptide. The transformation of arginine into 
ornithine proceeds stepwise and most likely in a random pattern. It ends when all seven arginine 
units in GRRRRRRRG (pI: 12.78) [12] have been transformed into GOOOOOOOG (pI: 5.52). 
Assuming a random reaction pattern also means that 176 different reaction intermediates can be 
formed.  
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Scheme 3.1: Transformation of GRRRRRRRG into GOOOOOOOR (G: L-glycine, R: L-
arginine, O: L-ornithine; stereochemistries not shown)). In each step, urea is hydrolytically 
cleaved off L-arginine to form L-ornithine. Note that the left side of the oligopeptide is bound to 
dopamine, which is anchored at the surface of the central iron/iron oxide nanoparticle of the 
nanoplatform. 
 
The posttranslational arginase sensors utilize cyanine dyes as FRET (Förster Resonance Energy 
Transfer) probes [13]. Cyanine 5.5 (donor) and cyanines 7.0/7.5 (acceptors) form attractive 
FRET-pairs, as indicated in Scheme 2, because of the significant spectra overlap between the 
fluorescence spectrum of cyanine 5.5 and the absorption spectra of both, cyanine 7.0 and 7.5. 
Furthermore, all cyanine dyes are characterized by their large molecular extinction coefficients 
and their narrow absorption and emission bands [14]. It should be noted that cyanine dyes have 
very short fluorescence lifetimes in the range of 200 to 350ps in water [15]. Therefore, they are 
essentially not quenched by oxygen. Cyanine dyes have reasonable fluorescence quantum yields 
ranging between 5 and 10 percent in aqueous buffers and in-vivo [16]. 
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Scheme 3.2: Spectral overlap between the potential Förster Resonance Transfer pairs Cyanine 
5.5/Cyanine 7.0 and Cyanine 5.5/Cyanine 7.5. The absorption and emission spectra of the 
cyanines are normalized. From this estimation, the spectral overlap in both FRET pairs appears 
to be of the same order of magnitude. Information from www.lumiprobe.com was utilized in 
preparing this scheme. 
 
 
 
66 
 
 
 
Figure 3.2: Cyanine Dyes used in this study. The extended structure of cyanine 7.5 is marked in 
gray. The synthesis of the cyanine dyes is described in the Experimental section.  
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3.3. Results and Discussion 
 
The nanoplatforms for arginase detection were designed from the following components: 
1) The central Fe/Fe3O4 core/shell nanoparticle. As transmission electron microscopy (TEM) 
indicates, the average Fe(0) core diameter of the Fe/Fe3O4-nanoparticles is 17±0.5 nm and 
the Fe3O4 shell thickness of 3.0±0.5 nm. The polycrystalline nanoparticles were synthesized 
synthesized by thermal decomposition of Fe(CO)5 in the presence of oleylamine and 
hexadecylammonium chloride (HADxHCl) using 1-octadecene (ODE) as solvent[17]. The 
optimization of this synthetic procedure by Dr. Hongwang Wang is described in the 
“Synthetic Procedures” section below. Dopamine was chosen as organic coating of the 
Fe/Fe3O4-nanoparticles, because, as a typical catechol, it strongly adhers to the Fe(III)-
centers of magnetite (Fe3O4), with a binding constant of (conservatively estimated) 10
20l mol-
1 [18]. Dopamine also increases the water-dispersibility of the inorganic nanoparticles to > 5 
g L-1 [19], which is mandatory for their use in aqueous buffers.  
2) Either cyanine 7.0 or cyanine 7.5 was tethered by means of stable amide bonds to the primary 
amine functions of dopamine. Both near-infrared dyes were selected as FRET acceptors, 
together with cyanine 5.5 as FRET donor (see below). It is noteworthy that the fluorescence 
lifetime of cyanines in water is too short to observe significant plasmonic quenching effects 
(also known as dipole-surface energy transfer (SET) [20]) between the central Fe/Fe3O4 
nanoparticle and the attached cyanines. This is a substantial design change in comparison 
with earlier nanoplatforms from the Bossmann group, in which tetracarboxyphenyl-porphyrin 
(TCPP), was used as a fluorophore. TCPP shows fluorescence lifetimes in the nanosecond 
range, which increases SET significantly. The number of cyanine 7.0 or 7.5 FRET acceptors 
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per nanoparticle was estimated to 70±5, based on their Vis-absorption spectra, and assuming 
that the spectra did not significantly changed when attached to the inorganic nanoparticles.  
3) Cyanine 5.5 was tethered to by means of the oligopeptide GRRRRRRRG (GR7G) to the 
dopamine-covered Fe/Fe3O4 nanoparticles. The synthesis of the oligopeptide, and the 
attachment of GR7G to the primary amine functions of the dopamine-coated nanoparticles 
were performed following procedures that were previously optimized in the Bossmann group 
[21, 22]. Cyanine 5.5 was attached to the N-terminal glycine of GR7G while the oligopeptide 
was still bound to the resin, thus eliminating the possibility of unwanted side reactions. As 
shown in Scheme 2, cyanine 5.5 was chosen as FRET donor. Based on UV/Vis spectroscopy, 
we have estimated that 45±5 cyanine 5.5 dyes were attached to the inorganic nanoparticles 
via GR7G tethers.  
 
 
Figure 3.3: Transmission Electron Micrographs of the nanoplatforms for arginase detection, 
recorded by Assistant Prof. Dr. Emily McLaurin using the FEI Tecnai G2 Spirit BioTWIN, 
120KV (GATAN digital imaging system and HAADF detector) TEM of the Nanotechnology 
Innovation Center at Kansas State University. A: dopamine-coated Fe/Fe3O4 nanoparticles; B: 
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dopamine-coated Fe/Fe3O4 nanoparticles featuring GR7G-attached cyanine 5.5 and tethered 
cyanine 7.5; C: dopamine-coated Fe/Fe3O4 nanoparticles featuring GR7G-attached cyanine 5.5 
and tethered cyanine 7.0). C: dopamine-coated Fe/Fe3O4 nanoparticles featuring GR7G-attached 
cyanine 5.5 and tethered cyanine 7.0).  
 
Upon excitation at 680 nm, cyanine 5.5 reaches its excited singlet state, which spectrally 
overlaps with the absorption spectra of both, cyanine 7.0 and cyanine 7.5. The general equation 
for FRET processes is: 
𝐸 =  
𝑘𝐸𝑇
𝑘𝑓+𝑘𝐸𝑇+∑ 𝑘𝑖
=
1
1+(
𝑟
𝑅0
)
6      Equation 1 
 
E: FRET efficiency, kET: rate of energy transfer, kf: radiative decay rate, ki’s: rate constants of 
any other occurring deactivation processes, r: distance between donor and acceptor, R0: Förster 
radius at which the energy transfer efficiency is 50%.  
 
The Förster radii for cyanine dyes are ranging from 5 and 8 nm [23]. The maximal length 
of both oligopeptides GR7G and GO7G is 3.2 nm. Considering the principal geometry of the 
nanoplatform, cyanine 5.5 can easily undergo FRET with both, cyanine 7.0 and cyanine 7.5, 
because it is within the Förster radius of more than one FRET-acceptor. Since FRET processes 
feature a r-6 dependence of the distance between donor and acceptor, changes in tether mobility 
will directly either decrease or increase the FRET efficiency.  It is our paradigm that the 
chemical transformation from arginine to ornithine is causing exactly this effect.  
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3.3.1. Calibration of the Nanoplatforms  
Nanoplatform 1 (FRET pair cyanine 5.5 / cyanine 7.0) and nanoplatform 2 (FRET pair cyanine 
5.5 / cyanine 7.5) were dispersed in PBS (1x phosphate buffered saline) (1mg / mL). The 
dispersion was then sonicated for 10 min. 70 μL of this stock solution was added to a series of 
30μL arginase dilutions in 2900μL of dextran/PBS (10mg/ml) solution. The concentration was 
ranging from 5.22 x 10-6 to 5.22 x 10-13 moles of arginase II per liter of 1x PBS. Recombinant 
Arginase II was purchased from Sigma/Aldrich. After adding the nanoplatform for arginase 
detection, the dispersion was incubated at 37oC for 1h. The resulting fluorescence was then 
measured using a Fluoromax 2 spectrofluorometer at 25oC, excitation wavelength 680 nm. The 
results are shown in Figures 3.4 to 3.11. 
 
Figure 3.4: Steady-state fluorescence spectra of nanoplatform 1 (FRET pair cyanine 5.5 / cyanine 
7.0) in PBS. Dark green line: PBS; light green line: 5.22 x 10-6 M arginase II in PBS; brown line: 
nanoplatform 1 in PBS in the absence of arginase after 1h of incubation at 37oC; blue line: 
nanoplatform 1 in PBS after incubation with 5.22 x 10-6 M arginase II in PBS at 37oC.  
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As Figure 3.4 shows, dual fluorescence from cyanine 5.5 (λmax = 723nm) and cyanine 7.0 
(λmax = 794nm) is observed. After incubation with arginase II, an increase in cyanine 7.0 
fluorescence is discerned, which indicates that FRET increases upon conversion of arginine to 
ornithine. It is noteworthy that the fluorescence of nanoplatform 1 increased after incubation 
with arginase II. I earlier studies, it was found that arginine was capable of forming a complex 
with a cyanine dye, which resulted in fluorescence quenching [24]. A similar effect is observed 
here, with the exception that cyanine 5.5 is tethered to GR7G, which results in an “infinite” 
binding constant. The fluorescence quantum yield of nanoplatform 1 increases upon conversion 
of arginine to ornithine, because the latter does not form complexes with cyanine 5.5. 
 
Figure 3.5: Steady-state fluorescence spectra of nanoplatform 1 (FRET pair cyanine 5.5 / cyanine 
7.0) in PBS. Fluorescence spectra for the whole calibration (5.22 x 10-6 M to 5.22 x 10-13 M of 
arginase II in PBS, incubation at 37oC for 1h). Dark blue line: 5.22 x 10-6 M or arginase II; blue 
line: 5.22 x 10-7 M; light blue line: 5.22 x 10-8 M; pink line: 5.22 x 10-9 M; red line: 5.22 x 10-10 
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M; brown line: 5.22 x 10-11 M, gray line: 5.22 x 10-12 M; black line: 5.22 x 10-13 M of arginase II 
in PBS.  
 
 
 
Figure 3.6: Steady-state fluorescence spectra of nanoplatform 1 (FRET pair cyanine 5.5 / cyanine 
7.0) in PBS. Fluorescence spectra for the whole calibration (5.22 x 10-6 M to 5.22 x 10-13 M of 
arginase II in PBS, incubation at 37oC for 1h). Dark blue line: 5.22 x 10-6 M or arginase II; blue 
line: 5.22 x 10-7 M; light blue line: 5.22 x 10-8 M; pink line: 5.22 x 10-9 M; red line: 5.22 x 10-10 
M; brown line: 5.22 x 10-11 M, gray line: 5.22 x 10-12 M; black line: 5.22 x 10-13 M of arginase II 
in PBS.  
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Most interestingly, the observed FRET efficiency is strongest after 1h of incubation with the 
highest arginase II concentration and weakest in the absence of arginase. This finding is 
providing experimental evidence in favor of our paradigm: GO7G possesses the higher mobility 
than GR7G. Furthermore, complex formation between cyanine 7.0 and arginine is not observed. 
 
  
 
Scheme 3.3: Paradigm for the observed FRET efficiency as a function of arginase II 
concentration in nanoplatform 1. Black dots: glycine; brown dots: arginine, light blue dots: 
ornithine. A: FRET is inefficient before reaction of the tether with arginase II. B: FRET is 
strongest when virtually all arginine units have to be converted to ornithine. 
 
The calibration curve for nanoplatform 1 is shown in Figure 3.7. Plotting the quotient of 
the integrated fluorescence bands of cyanine 5.5 (710 to 730nm) and cyanine 7.0 (760 to 840nm) 
vs. the decadic logarithm of arginase II concentration yielded the best (=most sensitive) results. 
Based on the experimental error of +/- 7 percent (rel.), the LOD of nanoplatform 1 under the 
experimental conditions described here is picomolar.  
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Figure 3.7: Calibration curve for nanoplatform 1 measuring arginase II (Sigma/Aldrich) activity 
in PBS. The plot shows the quotient of the integrated fluorescence bands of cyanine 5.5 (710 to 
730nm) and cyanine 7.0 (760 to 840nm) as a function of log10 of arginase II concentration. The 
error from three repetitions was determined to 7% (rel.). Based on this error, the LOD (limit of 
detection) of nanoplatform 1 is picomolar.  
Nanoplatform 2 (FRET pair cyanine 5.5 / cyanine 7.5) was tested/calibrated using the 
same protocols and procedures as described for nanoplatform 1. The only principal difference 
between the two nanoplatforms is that cyanine 7.5 is tethered to the dopamine coated Fe/Fe3O4 
nanoparticles instead of cyanine 7.0. Although both nanoplatforms are very similar in their 
chemical composition, we cannot exclude minor differences in nanoparticle diameter, dopamine 
coating and tethering efficacy to fluorescent dyes and GR7G. However, they should not account 
for the major differences in photophysical behavior between the two nanoplatforms.  
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The most striking difference between the photophysical behaviors of nanoplatforms 1 and 
2 is that the latter does not show increased FRET efficiency with increased arginase II 
concentration and incubation time. For nanoplatform 2, a significant fluorescence increase over 
the whole observed fluorescence range is observed.  This permits the calibration of nanoplatform 
2. However, due to the absence of FRET, its LOD is only at 10-10 M of arginase II concentration, 
which is two orders of magnitude less than the LOD of nanoplatform 1.  
 
Figure 3.8: Steady-state fluorescence spectra of nanoplatform 2 (FRET pair cyanine 5.5 / cyanine 
7.5) in PBS. Dark green line: PBS; light green line: 5.22 x 10-6 M arginase II in PBS; brown line: 
nanoplatform 2 in PBS in the absence of arginase after 1h of incubation at 37oC; blue line: 
nanoplatform 2 in PBS after incubation with 5.22 x 10-6 M arginase II in PBS at 37oC.  
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Figure 3.9: Steady-state fluorescence spectra of nanoplatform 2 (FRET pair cyanine 5.5 / cyanine 
7.5) in PBS. Fluorescence spectra for the whole calibration (5.22 x 10-6 M to 5.22 x 10-13 M of 
arginase II in PBS, incubation at 37oC for 1h). Dark blue line: 5.22 x 10-6 M or arginase II; blue 
line: 5.22 x 10-7 M; light blue line: 5.22 x 10-8 M; brown line: 5.22 x 10-9 M; gray line: 5.22 x 10-
10 M; black line: 5.22 x 10-11 M of arginase II in PBS.  
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Figure 3.10: Steady-state fluorescence spectra of nanoplatform 2 (FRET pair cyanine 5.5 / 
cyanine 7.5) in PBS. Fluorescence spectra for the whole calibration (5.22 x 10-6 M to 5.22 x 10-13 
M of arginase II in PBS, incubation at 37oC for 1h). Dark blue line: 5.22 x 10-6 M or arginase II; 
blue line: 5.22 x 10-7 M; light blue line: 5.22 x 10-8 M; brown line: 5.22 x 10-9 M; gray line: 5.22 
x 10-10 M; black line: 5.22 x 10-11 M of arginase II in PBS. 
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Figure 3.11: Calibration curve for nanoplatform 2 measuring arginase II (Sigma/Aldrich) activity 
in PBS. The plot shows the quotient of the integrated fluorescence bands of cyanine 5.5  and 
cyanine 7.5 over the complete fluorescence range (700 to 900nm) as a function of log10 of 
arginase II concentration. The error from three repetitions was determined to 5% (rel.). Based on 
this error, the LOD (limit of detection) of nanoplatform 2 is 10-10 M.  
 
What could be the reason for the observed differences? According to reference 24, 
cyanine dyes form complexes with cationic aromatic compounds, which results in fluorescence 
quenching. Besides arginine, a fraction of the dopamine ligands at the Fe3O4 surface of the 
central nanoparticle is also quaternized in PBS. Both cyanine dyes are negatively charged in 
PBS, due to the deprotonation of their sulfonic acid group. The only chemical difference between 
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cyanine 7.0 and cyanine 7.5 is the existence of two additional fused benzene rings.  Apparently, 
the presence of extended aromatic ring systems in cyanine 7.5 units favors their adsorption at the 
dopamine-coated interfaces. This enables more efficient fluorescence deactivation of cyanine 7.5 
and, therefore, distinctly less fluorescence occurring from cyanine 7.5. However, this does not 
explain the observed fluorescence increase of nanoplatform 2 with increased arginase II 
concentration and incubation time. Therefore, we have to assume that complex formation 
between arginine and cyanine 7.5 occurs as well. 
 
 
Scheme 3.4: Paradigm for the observed FRET efficiency as a function of arginase II 
concentration in nanoplatform 2. Black dots: glycine; brown dots: arginine, light blue dots: 
ornithine. A: FRET can occur between cyanine 5.5 and 7.5 before reaction with arginase II. 
However, complexation of both cyanines with quaternized arginine- and dopamine-units 
decreases their fluorescence quantum efficiencies. B: FRET between cyanine 5.5 and cyanine 7.5 
does not occur after conversion of arginine to ornithine in the tether. However, the total 
fluorescence efficiency of both cyanine dyes increases due to reduced complex formation with 
quaternized organic bases. 
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3.3.2. Arginase II Concentration in Mouse Tissues 
The tissue samples of BALB/c mice bearing 4T1 mammary tumors were obtained from 
Dr. Tej B. Shrestha in the group of Prof. Dr. Deryl L. Troyer, DMV, Department of Anatomy & 
Physiology at Kansas State University. The animal handling procedures are described in detail in 
reference [25]. The mouse tissue was harvested after the mice were euthanized 26d after tumor 
initiation in mammary fatpad #11. The mouse tissue was then homogenized following 
procedures that were previously established in collaboration with the group of Dr. Troyer, DVM 
[26]. All measurements of arginase II in tissue samples were performed using 2900 μL of 
PBS/Dextran, 30 μL of tissue extract and 70 μL of nanoplatform 1 dispersion in PBS/dextran. 
Assay controls were using 2970μL of PBS/Dextran and 30 μL of tissue extract. The 
solutions/dispersions were incubated for 60 min at 37oC, followed by measuring their 
fluorescence spectra at 25oC using a Fluoromax 2 device. The results are summarized in Figures 
3.12 to 3.14 and Table 3.1.  
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Figure 3.12: Steady-state fluorescence spectra of nanoplatform 1 (FRET pair cyanine 5.5 / 
cyanine 7.0) in PBS/Dextran (3.0 mL) in the presence of 30μL tissue extract from core regions 
of murine 4T1 tumors. Blue lines: nanoplatform 1 in the presence of tissue extract after 1h of 
incubation at 37oC. Black line: nanoplatform 1 in PBS after 1h of incubation at 37oC. Gray line: 
fluorescence of 30μL tissue extract from core regions of murine 4T1 tumors in PBS/Dextran (3.0 
mL).  
As summarized in Figure 3.12, all five tumor core samples obtained from BALB/c mice 
bearing 4T1 mammary tumors show similar fluorescence behavior, which translated into 
similar arginase II concentrations. The exact concentrations were calculated using the calibration 
curve for nanoplatform 1 (Figure 3.7) and are summarized in Table 3.1. These measurements are 
making use of the “ratiometric principle” by monitoring two emission bands at the same time, 
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and then calculating the ratio between them [27]. The major advantage of ratiometric detection 
methods is that the measurement is becoming virtually independent of the influence of the exact 
nanoplatform concentration and the biological matrix on the fluorescence measurements. 
 
 
Figure 3.13: Steady-state fluorescence spectra of nanoplatform 1 (FRET pair cyanine 5.5 / 
cyanine 7.0) in PBS (3.0 mL) in the presence of 30μL tissue extract from boundary regions of 
murine 4T1 tumors. Blue lines: nanoplatform 1 in the presence of tissue extract after 1h of 
incubation at 37oC. Black line: nanoplatform 1 in PBS after 1h of incubation at 37oC. Gray line: 
fluorescence of 30μL tissue extract from boundary regions of murine 4T1 tumors. 
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It is noteworthy that four tissue samples from the boundary regions of murine 4T1 
tumors result in similar photophysical behavior of nanoplatform 1, whereas one tissue sample 
was clearly different, resulting in a different fluorescence measurement. Since this is a syngeneic 
mouse model (possessing an intact immune system), it is very likely that one mouse developed a 
(weak) immune response to the tumor, resulting in a lower local arginase II activity. A 
comparison between the fluorescence spectra of tumor core samples and tumor boundary 
samples in Figures 3.12 and 3.13 clearly indicates that the intensity of the fluorescence spectra 
resulting from each tissue group are different. This may be caused by the presence of different 
proteins in tumor core and boundary regions. Nevertheless, the ratiometric principle is working 
well, permitting a direct comparison of the arginase II concentrations in both kinds of tissue (see 
Table 3.1).  
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Figure 3.14: Steady-state fluorescence spectra of nanoplatform 1 (FRET pair cyanine 5.5 / 
cyanine 7.0) in PBS (3.0 mL) in the presence of 30μL tissue extract from presumably non-
cancerous regions of murine 4T1 tumors. Blue lines: nanoplatform 1 in the presence of tissue 
extract after 1h of incubation at 37oC. Black line: nanoplatform 1 in PBS after 1h of incubation at 
37oC. Gray line: fluorescence of 30μL tissue extract from presumably non-cancerous regions of 
murine 4T1 tumors. 
Principally, the fluorescence occurring from nanoplatform 1 in the presence of 
nanoplatform 1 is similar as observed with tumor core and boundary tissue samples (Figures 3.12 
and 3.13). However, differences in total fluorescence intensity can be discerned here as well. 
Again, the ratiometric principles permits the comparison of all findings shown in Figures 3.12 to 
3.14.  
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Table 3.1: Calculated Arginase II Concentrations in Tissue Samples Collected from BALB/c 
Mice Bearing 4T1 Tumors in a Mammary Fatpad. Nanoplatform 1 was used to collect the 
fluorescence data, as described above. 
Tissue ∫ 𝐼𝑑𝜆
730
710
∫ 𝐼𝑑𝜆
840
760
 
 
Arginase II 
Concentration / M 
Tumor core 1 1.77 1.2 x 10-7 
Tumor core 2 1.78 1.1 x 10-7 
Tumor core 3 1.67 3.9 x 10-7 
Tumor core 4 1.74 1.8 x 10-7 
Tumor core 5 1.73 2.1 x 10-7 
Tumor boundary 1 1.15 7.1 x 10-6* 
Tumor boundary 2 1.19 5.1 x 10-6 
Tumor boundary 3 1.16 7.0 x 10-6* 
Tumor boundary 4 1.15 7.1 x 10-6* 
Tumor boundary 5 1.38 9.8 x 10-7 
Presumably healthy 
tissue from tumor mouse 1 
1.68 3.8 x 10-7 
Presumably healthy 
tissue from tumor mouse 2 
1.74 1.8 x 10-7 
Presumably healthy 
tissue from tumor mouse 3 
1.61 4.8 x 10-7 
Presumably healthy 
tissue from tumor mouse 4 
1.65 4.1 x 10-7 
Presumably healthy 
tissue from tumor mouse 5 
1.73 2.1 x 10-7 
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3.4. Conclusions 
Nanoplatforms for arginase detecting were developed, comprised of  a central, dopamine-
covered Fe/Fe3O4 nanoparticle and the FRET pairs cyanine 5.5 / 7.0 (nanoplatform 1) and 
cyanine 5.5 / 7.5 (nanoplatform 2). Cyanine  5.5 was tethered to the central nanoparticle via  the 
oligopeptide GR7G. Cyanine 7.0 was linked directly to the central inorganic nanoparticle.  
Nanoplatform 1 performed superior, permitting arginase II detection down to picomolar levels, 
while providing a very wide range of measurement from 5 x 10-6 to 10-12 M.  
 
We have utilized nanoplatform 1 for the determination of arginase II levels in tissue 
extracts from 4T1 tumor bearing white mice with exact immune system. Most interestingly, the 
arginase II concentration in the boundary region between tumor and presumably healthy tissue is 
on average 3.5 times higher than in the tumor core region, and 2.2 times higher than in 
presumably healthy tissue. From this data, two potentially important conclusions can be drawn: 
1) The immune suppression is highest in the cancer boundary regions. This is of importance for 
novel approaches to immunotherapy, which have to target the boundary region to be successful. 
2) There is a systemic immunodepression effect in cancer, which influences the biochemistry of 
the whole organism. Although immunodepression is strongest in the boundary region, it is by no 
means limited to that region. 
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3.5. Methods 
Cyanine 5.5 and dopamine coated core/ shell iron/ iron oxide nanoparticles were synthesized 
following the same procedure as explained in chapter 2. 
3.5.1. Cyanine 7.0 synthesis 
3.5.1(A) Synthesis of 4-(2,3,3-trimethyl-3H-indol-1-ium-1-yl)butane-1-sulfonate 
 
Figure 3.15: Reaction scheme for Synthesis of 4-(2,3,3-trimethyl-3H-indol-1-ium-1-yl)butane-1-
sulfonate  
6.37g 2,3,3-trimethyl-3H-indole and 10.89 g 1,2-oxathiane 2,2-dioxide(1/2 ratio) were 
dissolved in 30 mL of 1,2-dichlorobenzene, the reaction mixture was stirred at 120 oC under 
Argon for 12 hours. After cooling to room temperature, product was collected via vacuum 
filtration, and followed by washing with ether (3 ×10 mL). 5.91g 4-(2,3,3-trimethyl-3H-indol-1-
ium-1-yl)butane-1-sulfonate  was obtained as product [22,29]. 
 
3.5.1(B) Synthesis of (E)-2-chloro-3-(hydroxymethylene)cyclohex-1-enecarbaldehyde 
 
Figure 3.16: Reaction scheme for Synthesis of (E)-2-chloro-3-(hydroxymethylene)cyclohex-1-
enecarbaldehyde 
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A solution of 40 mL DMF in 40 mL of CH2Cl2 was chilled in a ice bath, and 37 mL of 
POCl3 in 35 mL of CH2Cl2 was added dropwise with stirring. Upon the completion of addition, 
10 g of cyclohexanone was added via a syringe. The formed solution was refluxed at 60 oC for 3 
hours. After cooling to room temperature, the solution was poured onto 200g crushed ice, and 
allowed to stand overnight. The yellow solid was collected by vacuum filtration, and further 
recrystallized in acetone [22,29]. 36% yield. 
 
3.5.1(C) Synthesis of sodium 4-((E)-2-((E)-2-(2-chloro-3-((E)-2-(3,3-dimethyl-1-(4-
sulfonatobutyl)-3H-indol-1-ium-2-yl)vinyl)cyclohex-2-en-1-ylidene)ethylidene)-3,3-
dimethylindolin-1-yl)butane-1-sulfonate (cyanine 7.0) 
 
 
Figure 3.17: Reaction scheme for Synthesis of sodium 4-((E)-2-((E)-2-(2-chloro-3-((E)-2-(3,3-
dimethyl-1-(4-sulfonatobutyl)-3H-indol-1-ium-2-yl)vinyl)cyclohex-2-en-1-ylidene)ethylidene)-
3,3-dimethylindolin-1-yl)butane-1-sulfonate (cyanine 7.0) 
0.5 g compound 4-(2,3,3-trimethyl-3H-indol-1-ium-1-yl)butane-1-sulfonate, 0.122 g 
compound (E)-2-chloro-3-(hydroxymethylene)cyclohex-1-enecarbaldehyde and 0.12 g NaOAc 
were heated in 13 mL of acetic anhydride at 70 oC for 40 min. After cooling to room 
temperature, the green solution was poured into 15 mL saturated lithium bromide water solution. 
The mixture was stirred at room temperature for 30 min. 30 mL of methylene chloride was added 
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to extract the product. The organic phase was washed with water (10 ×10 mL), and then dried 
over anhydrous MgSO4. After evaporation of solvent, the product was purified by column 
chromatography (Silica gel, eluted with ethyl acetate/ethanol 3/1 to 1/1 then 
CH2Cl2/ethanol/acetic acid 1/1/0.05) [22, 29]. 56% yield. 
 
3.5.2. Synthesis of sodium 4-((E)-2-((E)-2-(2-((2-carboxyethyl)thio)-3-((E)-2-(3,3-dimethyl-
1-(4-sulfonatobutyl)-3H-indol-1-ium-2-yl)vinyl)cyclohex-2-en-1-ylidene)ethylidene)-3,3-
dimethylindolin-1-yl)butane-1-sulfonate 
 
Figure 3.18: Reaction scheme for Synthesis of sodium 4-((E)-2-((E)-2-(2-((2-carboxyethyl)thio)-
3-((E)-2-(3,3-dimethyl-1-(4-sulfonatobutyl)-3H-indol-1-ium-2-yl)vinyl)cyclohex-2-en-1-
ylidene)ethylidene)-3,3-dimethylindolin-1-yl)butane-1-sulfonate. 
 
300mg of cyanine 7.0 (water soluble, symmetric), 52μL of 3-mercaptopropylacid (1.5 
equivalent) and 90μL of triethylamine (1.5 equivalent) were mixed in 2mL of dry DMF and 
stirred at room temperature for 20 hours under dark conditions. 10ml of ice cold ether was added 
dropwise to the reaction mixture, to precipitate out the product. Precipitated product was 
separated and dried under high vacuum [22,29]. 
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3.5.3. Cyanine 7.5 (water soluble) synthesis 
3.5.3(A) Synthesis of 4-(1,1,2-trimethyl-1H-benzo[e]indol-3-ium-3-yl)butane-1-sulfonate 
 
Figure 3.19: Reaction scheme for Synthesis of 4-(1,1,2-trimethyl-1H-benzo[e]indol-3-ium-3-
yl)butane-1-sulfonate 
A 50 mL two necked round bottom flask fitted with a magnetic stirrer and a condenser 
was flame dried. 1,1,2-trimethyl-1H-benzo[e]indole (1.0g, 4.78mmol) was dissolved in dry o-
dichlorobenzene (10 mL). 1,4-butanesultone (0.58mL, 5.73mmol) was added drop-wise under a 
continuous flow of argon. The reaction mixture was, then, allowed to heat up to 1300 C for 24h. 
The reaction mixture was allowed to cool down to room temperature to obtain a blue colored 
precipitate. The precipitate was triturated with ice-cold diethyl ether (40mL) for 15min. The 
precipitate was filtered through frit glass, washed with cold diethyl ether (3 x 5mL), dried in 
vacuum yielding 4-(1,1,2-trimethyl-1H-benzo[e]indol-3-ium-3-yl)butane-1-sulfonate [22,29]. 
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3.5.3(B) Synthesis of Cyanine 7.5 (water soluble, symmetric), sodium 4-(2-((E)-2-((E)-2-
chloro-3-((E)-2-(1,1-dimethyl-3-(4-sulfonatobutyl)-1H-benzo[e]indol-2(3H)-
ylidene)ethylidene)cyclohex-1-en-1-yl)vinyl)-1,1-dimethyl-1H-benzo[e]indol-3-ium-3-yl) 
Figure 3.20: Reaction scheme for Synthesis of sodium 4-(2-((E)-2-((E)-2-chloro-3-((E)-2-(1,1-
dimethyl-3-(4-sulfonatobutyl)-1H-benzo[e]indol-2(3H)-ylidene)ethylidene)cyclohex-1-en-1-
yl)vinyl)-1,1-dimethyl-1H-benzo[e]indol-3-ium-3-yl) 
 
0.58g compound 4-(1,1,2-trimethyl-1H-benzo[e]indol-3-ium-3-yl)butane-1-sulfonate, 
0.122 g compound (E)-2-chloro-3-(hydroxymethylene)cyclohex-1-enecarbaldehyde and 0.12 g 
NaOAc were heated in 13 mL of acetic anhydride at 70 oC for 40 min. After cooling to room 
temperature, the green solution was poured into 15 mL saturated lithium bromide water solution. 
The mixture was stirred at room temperature for 30 min. 30 mL of methylene chloride was added 
to extract the product. The organic phase was washed with water (10 ×10 mL), and then dried 
over anhydrous MgSO4. After evaporation of solvent, the product was purified by column 
chromatography (Silica gel, eluted with ethyl acetate/ethanol 3/1 to 1/1 then 
CH2Cl2/ethanol/acetic acid 1/1/0.05) [22,29]. 54% yield. 
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3.5.4. Synthesis of sodium 4-(2-((E)-2-((E)-2-((2-carboxyethyl)thio)-3-((E)-2-(1,1-dimethyl-
3-(4-sulfonatobutyl)-1H-benzo[e]indol-2(3H)-ylidene)ethylidene)cyclohex-1-en-1-yl)vinyl)-
1,1-dimethyl-1H-benzo[e]indol-3-ium-3-yl)butane-1-sulfonate 
 
Figure 3.21: Reaction scheme for Synthesis of sodium 4-(2-((E)-2-((E)-2-((2-carboxyethyl)thio)-
3-((E)-2-(1,1-dimethyl-3-(4-sulfonatobutyl)-1H-benzo[e]indol-2(3H) 
ylidene)ethylidene)cyclohex-1-en-1-yl)vinyl)-1,1-dimethyl-1H-benzo[e]indol-3-ium-3-
yl)butane-1-sulfonate 
250mg of cyanine 7.5 (water soluble, symmetric), 39μL of 3-mercaptopropylacid (1.5 
equivalent) and 62μL of triethylamine (1.5 equivalent) were mixed in 2mL of dry DMF and 
stirred at room temperature for 20 hours under dark conditions. 10mL of ice cold ether was 
added dropwise to the reaction mixture, to precipitate out the product. Precipitated product was 
separated and dried under high vacuum [22,29]. 
 
3.5.5. Synthesis of GR7G and GO7G oligopeptide sequences 
The GR7G and G07G consensus sequence were synthesized by standard solid phase 
peptide synthesis. Trityl-resin was used as a matrix polymer solid support. Peptide synthesis was 
completed in the same peptide synthesis tube by the repetitive steps in addition of specific amino 
acid, filtration and washings, accordingly. Commercially available N-terminal protected C-
terminal amino acids are used for the synthesis [28]. 
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The resin was preloaded into the peptide synthesis tube and swelled in dichloromethane 
(DCM) for 20 minutes and then filtered. DCM was washed away by five consecutive of N,N-
Dimethylformamide (DMF) washings. A mixture of Fmoc protected amino acid and O-
Benzotriazole-N,N,N',N'tetramethyl-uronium-hexafluoro-phosphate (HBTU) as coupling agent 
were added, swirled 30 minutes, and then filtered. This step was repeated once. Excess amino 
acid and the coupling agent were washed away by five DMF washings. Then 20% piperidine in 
DMF was used for N-deprotection. Subsequent amino acid coupling was performed after N-
deprotection. Both GR7G and G07G consensus sequences were synthesized using amino acid by 
amino acid from C-terminus to N-terminus [28]. 
 
3.5.6. Coupling of Cyanine 5.5 to the GR7G Oligopeptide Sequence 
Cyanine 5.5 was coupled to the N-terminal on the GR7G sequence following same 
coupling conditions as for an amino acid.  
Finally, the cyanine 5.5 conjugated GR7G consensus sequence was cleaved from the resin 
and also the side chain protecting groups were removed using a mixture of TFA, TIPS and water 
(95: 2.5 : 2.5). Cy5.5-GR7G was precipitated in cold ether and collected by centrifuging at 
10000rpm. After precipitation, several DMF washings were carried out to remove the excess of 
unreacted cyanine 5.5 and other reagents. Three final ether washings were carried out, in order to 
remove leftover DMF. 
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3.5.7. Coupling of Cyanine 5.5 to the GO7G Oligopeptide Sequence 
Cyanine 5.5 was coupled to the N-terminal on the GO7G sequence following same coupling 
conditions as for an amino acid.  
Finally, the cyanine 5.5 conjugated GO7G consensus sequence was cleaved from the resin 
and also the side chain protecting groups were removed using a mixture of TFA, TIPS and water 
(95: 2.5 : 2.5). Cy5.5-GO7G was precipitated in cold ether and collected by centrifuging at 10000 
rpm. After precipitation, several DMF washings were carried out to remove the excess of 
unreacted cyanine5.5 and other reagents. Three final ether washings were carried out, in order to 
remove leftover DMF. 
 
3.5.8. Sensor 1 development 
The published synthesis procedure (from Wang et al. (2014), is reproduced here. 
125 mg of dopamine coated Fe/Fe3O4 nanoparticles were dispersed in 2 mL of DMF. A 
solution of 3mmol of sodium 4-((E)-2-((E)-2-(2-((2-carboxyethyl)thio)-3-((E)-2-(3,3-dimethyl-1-
(4-sulfonatobutyl)-3H-indol-1-ium-2-yl)vinyl)cyclohex-2-en-1-ylidene)ethylidene)-3,3-
dimethylindolin-1-yl)butane-1-sulfonate (cyanine 7.0), 3.2 mmol of EDC, 1.7 mmol of DMAP in 
1 mL of DMF was added to this dispersion. After sonicating for 1 h, the nanoparticles were 
precipitated by centrifugation (10,000 RPM for 20 min), and thoroughly washed with DMF (1 
mL × 10). The recovered nanoparticles were redispersed in 2 mL of DMF, and to this dispersion, 
2.6 mmol of Cyanine 5.5 linked GR7G peptide sequence, 3 mmol of EDC, 2.6 mmol of DMAP 
in 1 mL of DMF was added. After sonicating for 1 h, the nanoparticles were precipitated by a 
magnet (0.55T), and thoroughly washed with DMF (1mL × 10). After drying in high vacuum, 
90-100 mg of nanoplatform was obtained. 
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3.5.9. Sensor 2 development 
The published synthesis procedure (from Wang et al. (2014), is reproduced here. 
125 mg of dopamine coated Fe/Fe3O4 nanoparticles were dispersed in 2 mL of DMF. A 
solution of 3mmol of sodium 4-(2-((E)-2-((E)-2-((2-carboxyethyl)thio)-3-((E)-2-(1,1-dimethyl-3-
(4-sulfonatobutyl)-1H-benzo[e]indol-2(3H)-ylidene)ethylidene)cyclohex-1-en-1-yl)vinyl)-1,1-
dimethyl-1H-benzo[e]indol-3-ium-3-yl)butane-1-sulfonate (Cyanine 7.5), 3.2 mmol of EDC, 1.7 
mmol of DMAP in 1 mL of DMF was added to this dispersion. After sonicating for 1 h, the 
nanoparticles were precipitated by centrifugation (10,000 RPM for 20 min), and thoroughly 
washed with DMF (1 mL × 10). The recovered nanoparticles were redispersed in 2 mL of DMF, 
and to this dispersion, 2.6mmol of Cyanine 5.5 linked GR7G peptide sequence, 3mmol of EDC, 
2.6 mmol of DMAP in 1 mL of DMF was added. After sonicating for 1 h, the nanoparticles were 
precipitated by a magnet (0.55T), and thoroughly washed with DMF (1mL × 10). After drying in 
high vacuum, 90-100 mg of nanoplatform was obtained. 
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Chapter 4 - Combinatorial phenotypic screen uncovers unrecognized family of 
extended thiourea inhibitors with copper-dependent anti-staphylococcal activity 
 
Acknowledgements 
I would like acknowledge all the collaborators, who contributed their knowledge and expertise 
towards the success of this project. Also I would like to thank Saran Kupul for excellent 
technical assistance and lab management. Some research of this study was supported in part by 
the University of Alabama at Birmingham Center for AIDS Research (UAB CFAR) and its 
Cytometry Core/Joint UAB Flow Cytometry Core which are funded by NIH/NIAID P30 
AI027767 and by NIH 5P30 AR048311, and NIH grant RO1 AI104952 to F.W  S.H.B. thanks 
the National Science Foundation for supporting this study (DMR-1242765 and CBET-1337438), 
as well as University of Alabama at Birmingham, Department of Medicine.   
This material described in chapter 4 has led to the following publication. Whereas the biological 
research was performed by the group at UAB, I was the principal chemistry graduate student on 
the team. I have discovered the novel complexation mode of Cu(I) by drugs with NNSN motif. 
My research has also established that drugs with modest Cu(I)-binding constants are suitable for 
activation via nutritional immunity. 
Combinatorial phenotypic screen uncovers unrecognized family of extended thiourea 
inhibitors with copper-dependent anti-staphylococcal activity 
Alex G. Dalecki1, Aruni P. Malalasekera2, Kaitlyn Schaaf1, Olaf Kutsch1, Stefan H. Bossmann2, 
Frank Wolschendorf1# 
1Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA;  
2Department of Chemistry, Kansas State University, Manhattan, KS, USA;  
 
101 
 
4.1. Abstract 
The continuous rise of multi-drug resistant pathogenic bacteria has become a significant 
challenge for the health care system. In particular, novel drugs to treat infections of methicillin-
resistant Staphylococcus aureus strains (MRSA) are needed, but traditional drug discovery 
campaigns have largely failed to deliver clinically suitable antibiotics. More than simply new 
drugs, new drug discovery approaches are needed to combat bacterial resistance. The recently 
described phenomenon of copper-dependent inhibitors has galvanized research exploring the use 
of metal-coordinating molecules to harness copper’s natural antibacterial properties for 
therapeutic purposes. Here, we describe the results of the first concerted screening effort to 
identify copper-dependent inhibitors of Staphylococcus aureus. A standard library of 10000 
compounds was assayed for anti-staphylococcal activity, with hits defined as those compounds 
with a strict copper-dependent inhibitory activity. A total of 53 copper-dependent hit molecules 
were uncovered, similar to the copper independent hit rate of a traditionally executed campaign 
conducted in parallel on the same library. Most prominent was a hit family with an extended 
thiourea core structure, termed the NNSN motif. This motif resulted in copper-dependent and 
copper-specific S. aureus inhibition, while simultaneously being well tolerated by eukaryotic 
cells. Importantly, we could demonstrate that copper binding by the NNSN motif is highly 
unusual and likely responsible for the promising biological qualities of these compounds. A 
subsequent chemoinformatic meta-analysis of the ChEMBL chemical database confirmed the 
NNSNs as an unrecognized staphylococcal inhibitor, despite the family’s presence in many 
chemical screening libraries. Thus, our copper-biased screen has proven able to discover 
inhibitors within previously screened libraries, offering a mechanism to reinvigorate exhausted 
molecular collections. 
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4.2. Introduction 
The advent of high throughput screening (HTS) technologies over thirty years ago 
revolutionized drug discovery efforts. Having apparently exhausted the readily identifiable 
repertoire of natural antibacterials derived from soil bacteria, HTS strategies began a renaissance 
in drug discovery, promising an effectively unlimited supply of novel compounds to combat the 
emerging threat of antibiotic resistance [1]. However, despite ever-expanding compound libraries 
and highly efficient screening methodologies, new classes of synthetic antibiotics have yet to 
materialize. The increasing concerns of returning to a pre-antibiotic era have proven severe 
enough to warrant attention and action by top governmental agencies [2,3]. 
Of the sixteen antibiotic classes used clinically, all but two were derived from 
environmental sources, and there is growing interest in returning to natural inspirations [1,4–6]. 
Among these inspirations lies metal-mediated innate immunity, by which the innate immune 
system directly modulates environmental levels of metals such as manganese, iron, zinc, and 
copper at the site of infection [7,8]. Through limitation, in the case of iron, zinc, and manganese 
or oversaturation, in the case of copper, the intrinsic properties of these ions are utilized to form 
a crucial line of defense against pathogens. Growing bodies of evidence point toward copper’s 
essentiality in particular. In many systems, including Mycobacterium tuberculosis, Pseudomonas 
aeruginosa, Listeria monocytogenes, and Streptococcus pneumoniae, bacterial copper resistance 
is linked to virulence; [9] conversely, attenuation of the ‘‘copper burst’’ within macrophages 
weakens the phagocytic response, promoting bacterial survival [10,11]. All sequenced bacteria 
possess at least a rudimentary level of copper resistance machinery,[12] varying from simple 
expression of an efflux pump,[13] to a complex network including pumps, sequestration 
proteins, oxidases, chaperones, and transcriptional regulators [14]. As free copper levels are 
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buffered below one ion per cell in both prokaryotes [15] and eukaryotes,[16] that even obligate 
intracellular bacteria retain resistance machinery further underscores copper’s profound role as 
an environmental and immunological insult [12]. 
Recent advances in our understanding of copper’s role in immunity have paralleled the 
rise of reports detailing the phenomenon of copper-dependent antibiotics. These compounds are 
highly inhibitory in the presence of copper, yet impotent in its absence. Example inhibitors have 
been described for Gram negatives,[17] Gram positives,[18] and mycobacteria,[19] as well as 
eukaryotic targets including pathogenic fungi [20] and cancer cells [21–23]. The broad range of 
potential targetable pathogens, coupled with the wide array of novel mechanisms of action, has 
generated interest in exploiting copper’s antibiotic properties [24,25]. However, until now, 
discoveries have been largely serendipitous, or based upon established metal-binding motifs; 
though well suited for chemical probes, these scaffolds are often poorly adaptable to therapeutic 
uses. Exploring the full potential of copper-mediated therapeutics requires new motifs and a 
directed discovery effort to identify proof-of-principle compounds. 
Here, we demonstrate for the first time the power of a copper focused HTS screening 
campaign. This approach is uniquely able to uncover new interactions between copper ions and 
compounds in existing chemical libraries, and their subsequent synergistic inhibitory activities. 
A copper-biased combinatorial screen against Staphylococcus aureus revealed nearly twice as 
many hits as a traditional, copper-blind campaign. A reoccurring extended thiourea motif, 
dubbed NNSN, featured novel copper binding properties, and was revealed by UV/Vis and NMR 
analysis to participate in a new interaction between the ligand and copper ion. This motif was 
highly inhibitory against S. aureus in a copper-dependent and copper-specific manner, yet was 
well tolerated in cell culture. Finally, despite their presence in many screening libraries, a 
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chemoinformatic meta-analysis demonstrated NNSNs as previously unrecognized 
antistaphylococcal agents, confirming the ability of copper-biased screens to discover new 
compounds hiding in existing chemical space. 
 
4.3. Methods 
4.3.1. Bacterial strains, antibiotics and compounds 
S. aureus clinical isolate SA3 (resistant to ampicillin, clindamycin, erythromycin, 
penicillin, and tetracycline) was characterized by and obtained in a de-identified manner from 
UAB Laboratory Medicine. Bacteria were routinely grown in Mueller Hinton (MH) medium 
(Oxoid Ltd, Basingstoke, Hampshire, England) overnight at 37 0C before inoculating plates 
according to assay conditions unless otherwise stated. All experiments were performed in 96-
well plates using MH medium or RPMI 1640 medium supplemented with trace metals. The trace 
metal mix was prepared as a 1000-fold stock solution containing 3 mM EDTA, 50 mM MgCl2, 
0.7 mM CaCl2, 80 mM NaMoO4, 168 mM CoCl2, 0.55 mM MnCl2, 0.7 mM ZnSO4, 2 mM 
FeSO4. All screened compounds were randomly taken from our 43,000 in-house compound 
library (Chembridge) or Chembridge’s Hit2Lead online library (www.hit2lead.com). Copper 
sulfate and all other commercial compounds were purchased from Sigma-Aldrich. Copper 
treated assays were supplemented with 50 mM CuSO4 unless otherwise indicated. Other metals 
were used at 100 mM or as indicated. 
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4.3.2. High throughput screening assay  
The HTS assay was conducted as published previously [18]. Briefly, all compounds were 
screened at 10 mM in duplicate plates run in parallel, one containing only medium (trace-copper 
conditions) and one containing medium supplemented with 50 mM CuSO4. S. aureus was added 
to each well to achieve a final optical density (OD600) of ~ 0.001 to 0.004 (1 : 1000 dilution of an 
overnight culture) in a total volume of 160 mL. All steps were performed using the Precision 
automated microplate pipetting system (BioTek). Plates were sealed with parafilm (Millipore) to 
minimize evaporation and incubated on a Heidolph Titramax 1000 plate shaker at 450 rpm at 37 
0C for 8 hours. Optical density, as a quantitative surrogate marker of bacterial growth, was 
determined using a Synergy HT plate reader (BioTek). Background correction was performed 
against wells containing only medium and compounds that decreased the growth of S. aureus 
were identified and further analyzed. 
 
4.3.3. HTS data analysis  
An in-house algorithm was utilized for analysis. The software package used MySQL and 
PHP as a server backend, and a web accessible HTML interface as the front end. Hits were 
defined based upon number of standard deviations (1 SD = 20%) from the overall mean, which 
averaged 94% across all copper-replete samples after blank correction and normalization to 
positive controls. Independent hits were compounds with less than 34% growth (3 SDs from the 
mean) in both standard and copper supplemented conditions. Copper dependent hits had under 
34%growth in the copper replete plate, with at least 40 percentage points (2 SD) more growth in 
copper trace plates (e.g., 20% growth in Cu-replete and 460% growth in Cu-trace plates). Inverse 
hits were the opposite, with under 34% growth in trace plates and at least 40 percentage points 
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more growth in replete plates. Substructure analysis was completed using the Open Babel 2.3.2 
chemistry toolbox, as installed on a Linux server.26 The SMARTS search string for non-cyclic 
thioureas was “[N;!R]C(=S)[N;!R],” while the NNSN substructure search was extended to  
“[#7][#6][N;!R]C(=S)[N;!R]” to include both cyclic and non-cyclic carbons and nitrogens. 
 
4.3.4. Structure Activity Relationship (SAR) Studies (SAR-by-catalogue) 
Active molecules were grouped based on the occurrence of structural motifs identified 
during visual and computational inspection of their chemical structures. Representative 
compounds and additional derivatives of each group were ordered from www. hit2lead.com. 
Activity was confirmed in dose response curves, of which we also determined the MIC (for 
details see below). Additional compounds featuring respective key motifs were identified in the 
Chembridge Hit2Lead online library using the search feature provided on the website 
(www.hit2lead.com). 
 
4.3.5. Determination of the minimal inhibitory concentration (MIC) 
Compounds were reconstituted in sterile DMSO (Sigma-Aldrich) typically at a 
concentration of 10 mM, then aliquotted, and stored at -80 0C. In some instances, a decline in 
potency of the compounds was noted over a period of 6 months and after repeatedly freezing and 
thawing reconstituted compounds. Compounds were diluted in 96-well in 2-fold increments, 
typically covering a concentration range from ~ 0.07 to 10 mM. Control wells containing media 
only (sterility control) and media with cells in the absence of compound with or without 50 mM 
copper were included as well. Assay conditions and incubation procedure were similar to that of 
the pilot screen. Dose–response curves were analyzed by determining the OD600 using a plate 
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reader (Synergy HT, BioTek). Data was analyzed as the average value of 3 wells with identical 
conditions and normalized to the proper growth controls. MIC was defined as the concentration 
at which growth was reduced by at least 85%. Additional transition metals were assayed in 
Roswell Park Memorial Institute 1640 medium without phenol red (RPMI; Life Technologies) 
and supplemented with a 1 : 1000 dilution of a copper-free trace metal mix (RPMI1640 + TM) to 
promote growth [27]. 
 
4.3.6. Eukaryotic toxicity assessment 
THP-1 cells were grown in standard RPMI plus 10% FBS. Cells were plated in RPMI at 100 000 
cells per well in a total volume of 200 mL in a 96 well plate, and challenged with compound in 
the presence or absence of 15 mM Cu for 24 hours. This copper concentration was well tolerated 
by THP-1 cells in our system and lies within the physiological range of copper levels in blood 
(10–25 mM) [28]. Viability was read using a Guava flow cytometer, through gating on live 
populations as assessed through forward and side scatter measurements. 
 
4.3.7. Characterization of metal complexation and structure modeling.  
The binding constants of CuBr in Trizma-HCl (pH = 7)/methanol (90/10 v/v) to 
compounds were determined according to the method of Benesi and Hildebrand [29]. The 
binding of Cu(II) and Cu(I) enhances the UV-absorption band of APT-6i at λmax = 235 nm. The 
differences in UV-absorption at λmax = 235 nm were used to calculate the binding constants KB. 
UV/Vis spectra of 8.3, 17, 41, 83, 170 and 410 nM of APT-6i were recorded in the absence and 
presence of 10 mM CuBr (Sigma-Aldrich, ACS grade) at 283 K in Trizma-HCl (pH = 
7.0)/methanol (1 : 1 v/v) using a Varian Cary 500 UV/Vis-NIR spectrophotometer and 4.0 mL 
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quartz cuvettes. The measurements were performed under argon to avoid Cu(I) oxidation to 
Cu(II). 
 
4.3.8. NMR Titrations:  
1H-NMR spectra were recorded using a Bruker Avance III, 600 MHz NMR-spectrometer 
at 298K.  Compound APT-6i was dissolved in deuterated acetone (6.25 mM), total volume: 400 
μl. Cu(I) was added from a stock solution of 1.5 x 10-4 M CuBr in deuterated acetone. 5 mL of 
CH3OD was added as internal standard (peak not shown). 
 
4.3.9. ChEMBL database meta-analysis.  
The ChEMBLdb relational database, version 20, was downloaded as the provided virtual 
machine (MyChEMBL; (30, 31). All SQL searches were conducted from a Linux command line 
interface. 
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4.4. Results 
4.4.1. Copper-biased HTS environment uncovers numerous copper-dependent hits. 
4.4.1(A) Nearly twice as many hits discovered through copper-biased screen as in a 
traditional screen. 
 
Figure 4.1: Parallel combinatorial scheme. Compounds from a master library are assayed twice 
in parallel, with one plate containing added copper sulfate, and the other containing only base 
medium. After adding S. aureus, both plates are incubated and viability is determined via 
OD600. Hits were classified by comparing growth values in both plates; the specific criteria used 
are detailed in the Methods. 
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Metal-based antibiotics have not yet advanced to clinical or veterinarian use and are 
therefore an attractive alternative to conventional antibiotics. Surprisingly, high throughput 
screening (HTS) solutions for the discovery of novel metal-related antibacterial activities do not 
exist. We focused our screen on compounds that display antibacterial properties through the 
interaction of copper because of its potential physiological relevance in the context of 
coppermediated innate immune functions [7,24], competitiveness over other physiological metal 
ions [32], and intrinsic antibacterial properties [33]. To reveal novel copper binding compounds 
not active in the absence of copper, we conducted a parallel screen, in which compounds were 
tested both under standard, traditional conditions, as well as in the presence of copper (Figure 
4.1). This strategy allowed us to comprehensively determine the spectrum of effects that copper 
ions might have on the antibacterial properties of potential bacterial inhibitors with copper-
related activities (enhancing or mitigating). Screening only in the presence of copper and testing 
only hits for their activity in the absences of copper would have missed a group of compounds 
that we classify as inverse hits. We chose to screen at 50 mM copper to enable detection of 
compounds with weaker copper-dependent activity (classified as secondary and tertiary hits), in 
order to better inform SAR, hit cluster expansion, and hit prioritization strategies.  
 
 Screening our 10 000 compound test library against a clinically isolated drug-resistant S. 
aureus strain (SA3) identified 129 total hits, or 1.29% of the overall number of compounds. 
Comparison of the hits from both the trace-copper screen (Figure 4.2A) and copper 
supplemented screen (Figure 4.2B) revealed 70 compounds (54%) that were similarly inhibitory 
under both screening conditions (copper independent hits) and 6 compounds (5%) that lost their 
antibacterial properties in the presence of copper (copper inverse hits).Importantly, 53 molecules 
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(41%) were found only in the presence of copper, demonstrating that copper-activated 
antibacterial activities occur rather frequently. Of the copper-dependent hits, over half (28) met 
our criteria for a primary hit, i.e., more than 90% inhibition. These copper-dependent hits 
represent hitherto unrecognized inhibitors, given that conventional screening campaigns for 
antibiotics do not contain sufficient and physiological quantities of copper ions.  
 
Figure 4.2: Combinatorial screening results.  
(A) Growth values of all 10 000 compounds in standard screening medium as normalized to 
plate controls. The red lines represent three standard deviations above and below the mean 
growth value as a cutoff for hits.  
(B) Growth values of all compounds in medium with copper added, as normalized to plate 
controls. Red, green, and blue circles are Primary (growth ≤10%, and greater than 2 SD below 
the –Cu plate), Secondary (10% > growth ≤ 20%, and greater than 2 SD below the –Cu plate), 
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and Tertiary (20% > growth ≤ 34%, and greater than 2 SD below the –Cu plate) dependent hits; 
grey boxes are independent hits; and orange diamonds are inverse hits. Some outliers may have 
fallen below the lower cut-off line but were classified as inactive because they did not meet hit 
criteria. 
 
4.4.1(B) Copper-dependent hits display significantly different chemical properties 
compared to the library as a whole 
Unfortunately, there is often a great disparity between molecules with desirable activities and 
molecules that are ‘‘druggable’’. To concentrate discovery efforts on promising compounds, 
coefficient (c log P) ≤ 5, hydrogen bond donors 5, and hydrogen bond acceptors ≤ 10. The 
criteria were later extended to include topological polar surface area (tPSA) ≤ 140 Å2 and 
rotational bonds (RB) ≤ 10. To visualize our results in aggregate, we compared Ro5 values of 
dependent hits, independent hits, inverse hits, and the screened library as a whole. Molecular 
weight only varied slightly between groups, and all were statistically indistinguishable from the 
library as a whole (Figure 4.3A). Rotational bonds and c log P values were slightly significantly 
different when comparing copper-dependent hits to the screened library (p = 0.0122 and 0.0116, 
respectively), though all three categories clustered toward the top of the c log P and bottom of 
the RB ranges (Figures 4.3B and 4.3C). Topological polar surface area (tPSA) differed greatly 
between dependent hits and all other categories (p < 0.0001), with the dependent hit median 
tPSA 38% lower than the library average (Figure 4.3D). The most striking comparison, however, 
came from numbers of hydrogen bond donors and acceptors. The screened library had a 
relatively even distribution of both acceptors and donors (Figure 4.3E), with a median of 4 
acceptors and 1 donor; while the median of copper-dependent hits clustered tightly at only 1 
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acceptor and 2 donors (Figure 4.3G). These structural differences may enable assembly or 
construction of custom libraries targeted towards enhanced copper-binding molecules. 
 
 
Figure 4.3: Lipinski Rule of Five characteristics.  
Aggregate (A) molecular weight, (B) rotational bonds, (C) calculated LogP (cLogP), and (D) 
topological polar surface area (tPSA) properties of copper-dependent hits (Cu Dep), copper-
independent hits (Cu Ind), and inverse hits (Inv). 
All groups were compared to the screened library as a whole (Library) using a one way ANOVA 
and Dunnett’s multiple comparisons test. * p < 0.05, ** p < 0.01, **** p < 0.0001. 
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Figure 4.3: Lipinski Rule of Five characteristics.  
(E) Heatmap comparisons of the hydrogen bond acceptors and donors within the entire screened 
library, (F) copper-independent hits, and (G) copper-dependent hits. 
 
4.4.2. Extended thiourea structure comprised a well-established hit cluster 
4.4.2(A) Novel NNSN motif associated with copper-dependent antistaphylococcal activity 
While our data indicates that the presence of physiologically relevant trace elements, 
specifically copper, reveals new hit molecules within a given compound collection, it is also 
important to demonstrate that the identified hits found by this alternative method are functionally 
relevant and responsive to optimizations. To substantiate this, we began a substructure analysis 
of our copper-dependent hits with the goal to identify repeatedly occurring chemical motifs and 
use such motifs as starting points for future SAR analysis. Thioureas (Figure 4.4A) dominated 
our copper-dependent hits, comprising 45 of the 53 total hits, or 85%. Such a high proportion 
greatly contrasted with the library as a whole, which featured only 570 thioureas in total (5.7%). 
Further, thioureas were not found to be generally active but rather possessed a specific copper-
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dependent activity, as only 7 of the 70 copper-independent hits contained a thiourea motif. This 
fraction was not significantly different in proportion from the entire library as judged by a chi-
squared analysis ( p = 0.119). Thus, not only did the screening conditions appear to have 
enriched our results specifically for the thiourea motif, but also have identified thioureas as the 
first example of a discrete chemical substructure identified by HTS that possesses strictly metal-
dependent antibacterial activities. 
Interestingly, 12 of the 45 thioureas featured an extendedthiourea structure, which we 
dubbed NNSN-motif (Figure 4.4B). No NNSN-motif was found among the copper-independent 
hits. All 12 copper-dependent NNSN molecules featured a linear thiourea structure, 
complemented by a heterocyclic ring system (pyrazolyl, tetrazolyl, thiazolyl, pyridinyl, 
pyrimidinyl or pyrazinyl) to form the full NNSN motif (Figure 4.4C). Molecular flexibility 
appeared to be essential for activity since rigid NNSN motifs with a cyclic thiourea structure as 
in triazolethiones (Figure 4.4D), imidazopyrimidine- thiones (Figure 4.4E) or pyrido-pyrimidine-
thiones (Figure 4.4F) were inactive. A substructure search within the structures of all 10 000 
randomly pickedmolecules that were included in our screen identified 30 total non-cyclic NNSN 
motifs; thus, the screen discovered 40% of all possible NNSN molecules. 
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Figure 4.4: A novel copper-binding NNSN motif and side groups.  
47 copperdependent hits contained a thiourea (A), with 12 featuring an extended NNSN motif 
(B) that consists of the thiourea base group paired with one of 6 possible heterocyclic nitrogen-
containing ring structures (C). Compounds with a rigid and inflexible NNSN motif (D, E and F) 
conferred no activity. (G) Full structure of APT-6i. 
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4.4.2(B) Adamantyl-bearing pyrazolyl-thioureas (APTs) yielded fruitful structure activity 
relationship analysis 
In order to probe whether NNSN-compounds have the potential of being further developed 
towards early lead status, we conducted a limited structure activity relationship study on 9 
commercially available pyrazolyl-thiourea derivatives featuring an adamantly group (Figure 4. 
5). Adamantyl bearing pyrazolyl-thioureas (APTs) were chosen because adamantyl substituents 
are known to improve drug stability and plasma half-life by impeding the access of hydrolytic 
enzymes through restricting or altering intramolecular reactivity,[36] and because adamantyl 
groups have no significant reactivity allowing us to link activity differentials to other 
substituents.[36] No activity was observed in medium without copper for any of these molecules, 
but in copper supplemented medium the compounds had minimum inhibitory concentrations 
(MICs) between 0.3 and 10 mM (Figure 4.5). 
 
Among the analogs tested, APT-6i (Figure 4.4G) exhibited excellent copper-dependent 
inhibition of S. aureus (Figure 4.6A), with a minimum inhibitory concentration of 0.3 mM. 
Additionally, APT-6i was relatively benign toward THP-1 cells, a human monocyte cell line 
(Figure 4.6A). Activity was also entirely copper specific, with no observed inhibition when 
growth media was supplemented with other transition metals such as Mn, Fe, Co and Zn (Figure 
4.6B). However, the presence of additional metals did not preclude activity, as full inhibition was 
restored upon co-incubation of Zn and Cu with APT-6i (Figure 4.6B). 
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Figure 4.5: Structure activity relationship analysis. Nine analogs of a promising hit molecule 
were purchased from the supplier (ChemBridge) and examined for antimicrobial activity.   
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Figure 4.6: APT-6i exhibits stark copper dependency and specificity.  
(A) Inhibitory effects of APT-6i against S. aureus (black squares) and THP-1 cells, a human 
monocyte line (open circles). APT-6i is active only in the presence of copper (orange line). (B) 
Activity of 10 µM APT-6i against S. aureus grown in RPMI to better resolve metal 
dependencies. Cu is included at 50 µM, and Fe, Mn, Co, and Zn are included at 100 µM. 
Inhibition is strictly copper-specific, and occurs in the presence of other ions, such as a Cu/Zn 
coincubation. All values are normalized to the respective 0 mM compound control (either with or 
without copper), and expressed as percentages of survival. 
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4.4.3. Pyrazolyl-thioureas are functionalized through unique copper-coordination 
chemistry 
To further examine the interaction between APT-6i and copper, we analyzed the metal–ligand 
complex using UV-Vis spectroscopy and 1H-NMR. UV-Vis titrations are a straightforward 
method to visualize metal–ligand complex formation, and revealed a main absorption peak at λ = 
235 nm, with intensity strongly dependent on the APT-6i concentration (Figure 4.7A). This peak 
represents an energy shift in electron orbitals, indicative of complex formation and subsequent p 
bonding between the copper ion and ligand. Further analysis through the Benesi–Hildebrand 
method [29] produced linear plots, confirming a 1 : 1 stoichiometry within the ligand–metal 
complex (Figure 4.7B). The binding constant of CuBr and APT-6i in Trizma/methanol was 
calculated to KB = 476,700 ± 1200 (L mol-1). 
 
 
Figure 4.7: APT-6i forms a unique copper complex. (A) UV/Vis absorption spectra of compound 
APT-6i in the presence of 3.3 mM Cu(I)Br in in Trizma-HCl (pH=7)/methanol (90/10 v/v). 
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Concentrations of APT-6i were 8.3 nM, 17 nM, 41 nM, 83 nM, 170 nM and 410 nM. (B) Benesi 
Hildebrand plots for determining the binding constant and molar absorption coefficients of APT-
6i with CuBr. 
 
As we were unable to obtain crystal structures of the Cu(I) and APT-6i complex, we relied on 
1H-NMR-titration with CuBr in deuterated acetone to discern the structure formed in solution 
(Figure 4.7C). Intriguingly, the 1H-NMR titration confirmed that the observed 1:1 complexation 
geometry is clearly different from canonical Cu(I)-thiourea complexes, which usually feature at 
least two thiourea ligands per metal cation. It is especially noteworthy that both thioamide 
groups, but not the thiocarbonyl group, take part in the observed complexation. Following the 
shift of peak position 4 from d = 5.931 to 5.984 ppm with increasing CuBr concentration (Figure 
4.7E), it is apparent that one of the aromatic carbons of the pyrazole unit is in close proximity to 
Cu(I) in solution, assuming that a CH3OD molecule (added as internal standard) is also 
coordinated to Cu(I) in order to obtain a slightly distorted tetrahedral geometry. The solution 
structure of the APT-6i-Cu(I) complex is the basis for the molecular modeling (Figure 4.8 A–C). 
From our modeling, it becomes clear that significant conformational changes are required to 
accommodate the complexation of a central Cu(I) cation (Figure 4.8 B and C). 
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Figure 4.7: (C) Overlay of the 1H-NMR spectra (Bruker Avance III, 600 MHz, 298 K) of 
compound APT-6i without CuBr (bottom), with 50 mM CuBr (middle), and with 100 mM CuBr 
(top) in deuterated acetone. Peak assignments correspond to panel D with A = adamantyl. The 
arrow indicates a copper responsive peak shift.  
(D) Structure of APT-6i showing relevant peak assignments and match with panel C. 
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Figure 4.7: (E) Shift of highlighted peak 4 with increasing concentrations of CuBr from panel C, 
indicating an interaction with copper ions at these sites. 
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Figure 4.8: The APT-6i and copper complex has unique coordination chemistry. The complex’s 
geometry was determined using UV Vis and 1H-NMR, shown in Figure. 4.7.  
(A) The (minor) resonance structure of APT-6i is able to form a complex with Cu(I). 
A 
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Figure 4.8:  
(B) 3D representation of uncomplexed APT-6i using the CHARMM force field, showing a 
relatively linear structure. Non-polar hydrogens are removed for clarity.  
(C) 3D model of the APT-6i/Cu(I)/CH3OD complex. Coordination twists the molecule from a 
linear structure to a bent configuration. Copper is represented as the orange sphere, with a D1-
methanol added to the coordination complex. Yellow sphere represents sulfur, blue are nitrogen 
atoms, grey are carbon atoms and white are polar hydrogens. 
 
 
 
 
 
B 
C 
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More importantly to drug discovery efforts, this novel complexation could potentially 
reopen the door to a wide array of otherwise unattractive compounds. Although thioureas readily 
complexes metal ions, and are thus logical candidates for discovery by the paradigm detailed 
here, they are often regarded as undesirable due to common hepatotoxicity and thyroid 
peroxidase inhibition [37]. Sulfur’s lack of participation in the complex suggests the possibility 
of bioisoteric substitution of other functional groups or atoms, negating toxicity while retaining 
complexation ability and antibacterial activity. Previous reports offer precedent, though results 
are expectedly mixed: some substitutions, such as cyanoguanidines, retained activity or increased 
therapeutic indices,38 while others lost biological activity [39]. A concerted SAR effort would 
likely produce new metal-complexing non-thioureas. 
  
4.4.4. Meta-analysis reveals NNSNs as previously unrecognized antistaphylococcal agents 
Having identified the NNSN motif as a promising and novel copper-dependent 
antibacterial structure, we examined whether this motif had previously been recognized for its 
therapeutic potential. We conducted a meta-analysis of published activities using the ChEMBL 
database, a publically available relational database containing over 13million activity records of 
1.4million compounds, taken from multiple sources including 2700 PubChem BioAssays and 
tens of thousands of primary literature reports [30]. The database facilitates tracking individual 
compounds through a large number of systems, such as biochemical assays, whole cell screens, 
and in vivo data, against prokaryotic and eukaryotic targets. Although ChEMBL does not 
generally include inactive hits, it is a rich repository of bioactive compounds in a variety of 
contexts. 
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Figure 4.9: Chemoinformatic search of the ChEMBL database. The ChEMBL chemoinformatic 
database was queried with the NNSN motif for similar molecules. Though the limited screen 
described here revealed 12 NNSNs with significant antibacterial effects, only a single NNSN 
with activity against S. aureus below 10 µM was found within the database.  
 
Querying the NNSN motif against the database returned 608 hits with recorded activity 
(Figure 4.9). Narrowing the search to only whole-cell activities against S. aureus returned only 
57 hits. Most of these activities, however, were pulled from batch synthesis efforts reported in 
the literature, rather than from a directed screening campaign. Of the entire set, 39 had reported 
MICs below 500 mM, and only 5 had MICs below 50 mM; of these, only a single compound had 
a MIC below 10 mM.40 Given that HTS are limited to testing only one concentration, often at 10 
mM, it is likely none of these compounds would have been found individually in a screening 
campaign, and, hence, would not have been identified as a hit series. 
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4.5. Discussion 
In this study, we report the results of the first high throughput screening (HTS) campaign 
for the discovery of copper-dependent antibacterial inhibitors. This strategy not only resulted in a 
much greater number of promising hit molecules than traditional screening methods, but also 
specifically revealed a previously unknown hit series, whose anti-staphylococcal activity escaped 
previous detection despite being present in many screening libraries. 
Though metal complexation screens could hypothetically proceed using any of the first 
row transition metals (Mn, Fe, Co, Ni, Cu, and Zn), copper offers the most attractive and most 
viable vehicle for synergistic inhibition. Copper’s antimicrobial properties are multifaceted, but 
ultimately stem from its relative proclivity toward stable ligand complexation when compared to 
other transition metal ions. This phenomenon is described by the Irving–Williams series, where 
complex stabilities are their lowest with manganese, increase in periodic fashion until maximum 
stability at copper, and finally decline at zinc [41]. Functionally, this gives copper a higher 
affinity for sulfur, oxygen, and nitrogen than any other physiologically relevant transition metal 
[42]. This affinity, combined with copper’s high redox potential, is often exploited in metallo-
proteins such as superoxide dismutases or cytochrome c oxidases, and as such is key to the 
normal function of both prokaryotic and eukaryotic cells. However, copper ions in excess readily 
displace or replace crucial metalloenzyme cofactors, attack vulnerable iron–sulfur clusters, and 
directly damage accessible amino acid residues [15]. Cumulatively, these effects heavily 
interfere with cellular function; as a result, all sequenced bacteria possess at least some level of 
copper resistance [12]. 
  As an antimicrobial, copper assaults numerous sites within the cell. Many bacteria 
have had specific targets identified (e.g., dehydratases in E. coli [43], aerobic nucleotide 
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synthesis in Streptococcus pneumonia [44], and heme biosynthesis in Neisseria gonorrhoeae 
[45], but outside of general mechanisms such as attacking iron–sulfur clusters in proteins, 
specific points of failure vary widely from organism to organism. The detected source of toxicity 
is simply the ‘‘weakest link,’’ or first component to fail. It is very likely some copper-dependent 
inhibitors feature a similar variety of mechanisms, especially if acting through general copper 
overload (as in the case of 8-hydroxyquinoline [20]. More targeted compounds may be capable 
of additional mechanisms as well. GTSM, for example, acts upon the electron transport chain of 
N. gonorrhoeae, with its spectrum of activity hypothesized to be explained through a particular 
bacterium’s reliance on aerobic respiration [17,25]. Yet, GTSM is also a potent copper-
dependent inhibitor of S. pneumoniae (ref. 25; unpublished observations), a facultative anaerobe 
lacking an electron transport chain. Thus, additional modes of action must be at play, indicating a 
multi-faceted mechanism of activity. Though the ‘‘magic bullet’’ paradigm of one drug-one 
target has dominated since its proposal by Paul Ehrlich a century ago,46 copper-dependent 
inhibitors may offer an alternative: since multiple individual targets could be vulnerable, 
development of resistance would be much more difficult than against traditional, single target 
antibiotics. 
 
The allure of copper’s anti-bacterial properties has not gone unnoticed [17–20,25,47–49]. 
Unfortunately, free copper ions have little therapeutic value due to their erratic reactivity [50–
53]. To pharmacologically control the activity of copper ions and direct them to a specific target, 
numerous chemosynthetic efforts have synthesized copper complexes with greatly enhanced 
antibacterial activities [47,54–58]. However, many of these rely on metal binding motifs that had 
analytical and technical purposes, rather than medicinal applications. Subsequent synthesis 
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efforts often prioritize advancing the frontiers of organo-metallo-chemistry (e.g. mixed ligand 
complexes), leaving biological considerations as a secondary focus. Consequently, structure 
activity relationship studies, such as exemplified by the clinically used metalloantibiotic 
bacitracin [59], are extremely rare. While powerful in its own right, the agnosticism of this 
chemosynthetic strategy toward biological considerations impedes its applicability to HTS 
discovery. Though we have begun exploring how to harness the potential of copper in chelate 
based metalloantibiotics, we still need HTS solutions to probe the existing chemical space for 
novel metal-related activities to facilitate discovery and development of innovative metal-
oriented therapeutics. 
  
 
 
4.6. Conclusion 
In summation, our work details the first concerted antibiotic HTS discovery effort to harness the 
activity of an unconventional antimicrobial, copper. These unique inhibitors have, until now, 
largely gone unnoticed within conventional screening libraries, offering a way to repurpose and 
reprobe existing chemical collections. Though therapeutically infeasible on its own, copper’s 
potential can be readily exploited through combination with small organic molecules, offering a 
promising new approach in the battle for novel antibacterials. 
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Appendix A - Spectral Analysis (Chapter 2) 
 
Figure A1: 1H-NMR of (4-carboxyphenyl)porphyrin (TCPP) (Varian, 400 MHz). 
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Figure A2: Mass spectrum of (4-carboxyphenyl)porphyrin (TCPP)  
C48H30N4O8 
Exact Mass: 790.21 
m/e: (M+H)+791.21 
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Figure A3: 1H-NMR of 3-(5-carboxypentyl)-1,1,2-trimethyl-1H-benzo[e]indol-3-ium      
(Varian, 400 MHz). 
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Figure A4: 1H-NMR of 4-(1,1,2-trimethyl-1H-benzo[e]indol-3-ium-3-yl)butane-1-sulfonate 
(Varian, 400 MHz). 
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Figure A5: 1H-NMR of Cyanine 5.5(Varian, 400 MHz). 
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 Figure A6: 13C-NMR of Cyanine 5.5(Varian, 400 MHz). 
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Appendix B - Mass spectral Predictions (Chapter 4) 
Calculated molar peaks for C21H25ClN4S   Found (M-1) peaks for C21H24ClN4S  
400.148845223 100.0     399.14027  100.0  
401.151814098 25.247685799    400.11207  32.443   
402.14644539  39.482274778    401.12801  43.180  
403.148865348 9.42133780043   402.09933  13.601  
404.145929417 2.58031685727   403.07903  4.7281   
405.146631923 0.443145002843 
(1)  
 
(2) 
 
Figure B (1) (2): Mass spectrum of C21H25ClN4S 
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(3) 
 
(4) 
 
 
Figure B: 
(3) Mass spectrum of C21H25ClN4S and Cu(I) complex formed at micromolar concentration 
range: (1:1 ratio) 
(4) The structure consistent with the complex formed at micromolar concentration range: (1:1 
ratio) 
 
 
N
N
H
N
S
HN
Cl
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Calculated peaks for C21H26N4OClS 
480.079084384 100.0  
480.998798585 37.0905660322 
482.071687129 90.1116654203 
482.968631521 32.9262775276 
484.043056234 26.3941213765 
 
Found peaks for C21H26N4OClS 
480.07907 21.201 
480.99879 7.790  
482.07171 18.922  
482.96862 6.916  
484.04306 5.542  
 
 
 
Figure B5: Mass spectrum of C21H26ClCuN4OS 
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Calculated peaks for C42H50Cl2CuN8S2   Found peaks for C42H50Cl2CuN8S2 
831.258680937 6.69308335001   831.25868 6.691  
832.222866887 4.37557054894   832.22293 4.380  
833.241333065 9.10552480002   833.24133 9.106  
834.180127148 5.39869010354   834.18021 5.399  
835.209772629 4.86998701706   835.20980 4.868  
836.118434462 2.57582364786   836.11844 2.577  
837.101586016 1.40926624196   837.10156 1.410 
 
  
 
Figure B6:  Mass spectrum of C42H50Cl2CuN8S2 complex 
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Figure B7:  Mass spectrum of C42H50Cl2CuN8S2 complex 
 
 
 
Figure B8:  Complex structure of C42H50Cl2CuN8S2  consistent with the mass spectrum 
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Calculated peaks for C24H32N4S    Found peaks for C24H32N4S  
408.234767738 100.0     409.24199  100.0 0 
409.237808811 28.5708719491   410.23315  33.255  
410.235157672 8.46243683171   411.22534  11.015  
411.235562523 1.60335922847   412.20772  2.898  
412.236657927 0.206573945737   413.11461  0.863 
 
Figure B9:  Mass spectrum of C24H32N4S 
 
Figure B10:  Mass spectrum of C24H32N4S 
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Peaks found for C24H34CuN4OS complex formed at micromolar range 
489.17425  7.155  
490.12755  2.745   
491.16090  4.1840  
492.10877  1.5401  
493.06142  0.5680  
 
Peaks calculated for C24H34CuN4OS complex formed at micromolar range  
489.174254513 100.0  
490.127536823 38.3361417666  
491.160909315 58.4683003114  
492.108754866 21.5264145111  
493.061392146 7.93871550432 
 
 
 
Figure B11:  Mass spectrum of C24H34CuN4OS complex formed at micromolar range  
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Peaks calculated for C24H34CuN4OS complex formed at millimolar range: 
879.428774413 100.0 
880.345468124 78.881   
881.351093445 86.012 
 
Peaks found for C24H34CuN4OS complex formed at millimolar range: 
879.42878 100.0 
880.34551 78.6593452815   
881.35110 85.9995952992 
 
 
Figure B12:  Mass spectrum of C24H34CuN4OS complex formed at millimolar range 
 
 
 
 
 
 
 
